System genetics in the rat HXB/BXH family identifies *Tti2* as a pleiotropic quantitative trait gene for adult hippocampal neurogenesis and serum glucose

Anna N. Grzyb^{1,2}, Rupert W. Overall^{1,2}, Jan Silhavy³, Petr Mlejnek³, Hana Malínská⁴, Martina Hüttl⁴, Irena Marková⁴, Klaus S. Fabel^{1,2}, Lu Lu⁵, Ales Stuchlik³, Robert W. Williams⁵, Michal Pravenec³, Gerd Kempermann^{1,2*}

¹ German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany

² CRTD – Center for Regenerative Therapies Dresden, Technische Universität Dresden, Fetscherstraße 105, 01307 Dresden, Germany

³ Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, 142 20, Czech Republic

⁴ Institute for Clinical and Experimental Medicine, Videnska 1958, 14021 Prague 4, 142 21, Czech Republic

⁵ Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, USA

* Corresponding author

E-mail: gerd.kempermann@dzne.de or gerd.kempermann@tu-dresden.de

Abstract

Neurogenesis in the adult hippocampus contributes to learning and memory in the healthy brain but is dysregulated in metabolic and neurodegenerative diseases. The molecular relationships between neural stem cell activity, adult neurogenesis, and global metabolism are largely unknown. Here we applied unbiased systems genetic methods to quantify genetic covariation among adult neurogenesis and metabolic phenotypes in peripheral tissues of a genetically diverse family of rat strains, derived from a cross between the spontaneously hypertensive (SHR/OlaHpcv) strain and Brown Norway (BN-Lx/Cub). The HXB/BXH family is a very well established model to dissect genetic variants that modulate metabolic and cardiovascular disease and we have accumulated deep phenome and transcriptome data in a FAIR-compliant resource for systematic and integrative analyses. Here we measured rates of precursor cell proliferation, survival of new neurons, and gene expression in the hippocampus of the entire HXB/BXH family, including both parents. These data were combined with published metabolic phenotypes to detect a neurometabolic quantitative trait locus (QTL) for serum glucose and neuronal survival. We subsequently fine-mapped a key phenotype to a locus that includes the telo2-interacting protein 2 gene (*Tti2*)—a chaperone that modulates the activity and stability of PIKK kinases. To validate variants in or near *Tti2* as a cause for differences in neurogenesis and glucose levels, we generated a targeted frameshift mutation on the SHR/OlaHpcv background. Heterozygous SHR-*Tti2*^{+/-} mutants had lower rates of hippocampal neurogenesis and hallmarks of dysglycemia compared to wild-type littermates. Our findings highlight *Tti2* as a causal genetic and molecular link between glucose metabolism and structural brain plasticity. In humans, more than 800 genomic variants are linked to *TTI2* expression, seven of which have associations to protein and blood stem cell factor concentrations, blood pressure and frontotemporal dementia.

47 **Author summary**

48 Metabolic and neurological disorders are often comorbid, suggesting that biological pathways
 49 which orchestrate peripheral homeostasis and the integrity of the nervous system intersect.
 50 The genetic architecture behind these relationships is still poorly described, in part because
 51 molecular processes in the human brain are very difficult to study. We thus used a rodent
 52 genetic reference population to investigate links between adult hippocampal neurogenesis—
 53 a cellular plasticity mechanism important for learning flexibility—and metabolism. We
 54 measured adult neurogenesis in the family of 30 HXB/BXH rat recombinant inbred strains,
 55 who are characterised by stable differences in metabolism, behaviour, and gene expression
 56 levels. Because gene variants affecting distinct traits segregated into different members of
 57 the family, we discovered that previously published phenotypes correlated to adult
 58 neurogenesis due to shared genomic sequence. We found that expression levels of *Tti2*—a
 59 part of a specialised protein chaperone complex regulating stability of PIKK kinases—were
 60 concomitantly influencing adult neurogenesis and serum glucose levels. In human
 61 populations hundreds of genomic variants regulate *TTI2* expression, potentially affecting
 62 brain function and glucose homeostasis.

Introduction

Epidemiological studies link components of the metabolic syndrome—a complex disorder characterised by the coexistence of obesity, insulin resistance, dyslipidaemia, and hypertension—to cognitive impairment and dementia [1]. Defective brain function is often seen as a consequence of longstanding metabolic deregulation. The full picture, however, is more complex. Several human phenome-wide association studies identified causal genetic loci that are shared between metabolic and neurological phenotypes [2–8], suggesting some degree of pleiotropy—a phenomenon whereby one gene variant affects multiple traits. Pleiotropy is widespread among model organisms [9–13] and humans [2,14–17] with an estimated median number of around six traits per locus [13]. Pleiotropic mutations can result in genetic covariance among phenotypes [10,12]. Cognition and metabolic homeostasis are both achieved through multiple elementary mechanisms at molecular, cellular, tissue, and inter-organ levels, some of which might be shared. To understand the biology underlying correlations between such complex functions, it is necessary to identify which exact processes are simultaneously affected by shared genetic variation.

Adult neurogenesis in the dentate gyrus (DG) of the hippocampus is required for cognitive flexibility of learning, efficient pattern separation and emotional processing in mammals [18], and thus embodies a functionally relevant and readily quantifiable parameter of hippocampal plasticity. In humans, according to the best available calculation, one third of dentate granule cells are born during adulthood [19]. The generation of new granule neurons in the DG is a complex multistep process, in the course of which neural precursor cell proliferation, as well as survival, maturation, and integration of newly born postmitotic cells are under the control of multiple genetic loci. Remarkably, cellular metabolism has been identified as a regulator of neural stem and progenitor cell maintenance, proliferation, and differentiation [20], yet the interactions of adult neurogenesis with systemic metabolism are far from being understood. Given the overall significance of metabolism for brain function in health and disease, there is

a high likelihood that direct causal links exist between structural brain plasticity and metabolic traits and states.

Natural genetic variation present in genetically diverse mouse populations contributes to up to ten-fold differences in the net production of new neurons [21,22]—values much larger than the induction achieved by environmental interventions within a single genetic background. This enormous genetic potential inherent in rodent strains can be utilised to dissect the molecular interaction networks not only underlying adult neurogenesis as such, but also its connections with homeostatic mechanisms in peripheral tissues.

We thus employed a family of 30 fully inbred recombinant HXB/BXH rat strains, which have been derived by reciprocal mating of a spontaneously hypertensive rat line (SHR/OlaIpcv, hereafter referred to as SHR) with the normotensive BN-Lx/Cub—a Brown Norway (BN) congenic rat with a mutation that causes a polydactyly-luxate phenotype [23,24]. Besides hypertension, SHR manifests other hallmarks of metabolic syndrome [25–27], as well as cognitive deficits [28,29], and brain morphological changes [30,31]. The HXB/BXH family were developed to map quantitative trait loci (QTL) for hypertension and morphological abnormalities associated with polydactyly-luxate syndrome [23,24], but they are of great utility for genetic mapping of a wider spectrum of phenotypes. The HXB/BXH family have become the most thoroughly characterised rat reference population within the Rat Hybrid Diversity Panel [32]. Over 200 metabolic, endocrinological, behavioural and developmental phenotypes, along with gene expression profiles in peripheral tissues, are publicly accessible in a FAIR-compliant format at the GeneNetwork database [33,34]. The stable genetic background of these recombinant inbred lines enables truly systemic integration of phenotypic and omics data [32]. Accordingly, the HXB/BXH family have been used to clone genes associated with several disease quantitative trait loci (QTL) and discover gene regulatory networks relevant for human diseases [26,27,35–41]. The family offer levels of genetic diversity comparable to human populations [42,43] and hence allow for the separation of phenotypes modulated by different sets of gene variants. Correlations between phenotypes, in turn, suggest shared genetic causality [10,44].

117 In the present study, we quantified adult hippocampal neurogenesis in all existing
 118 HXB/BXH family members and parents. We aimed to find out the extent of genetic
 119 correlations between neurogenesis and peripheral metabolism, and sought to identify
 120 common loci that cause these correlations. The data reported here were submitted into
 121 public databases as a part of the HXB/BXH phenome resource.

Results

Adult neurogenesis in HXB/BXH strains

We quantified adult hippocampal neurogenesis in DG of young male rats from all 30 HXB/BXH family members, as well as the parental founder strains BN and SHR. Numbers of proliferating stem and progenitor cells were estimated using immunohistochemistry against the Ki67 antigen (Fig. 1A, D). Dividing cells were also labelled with BrdU at 10 weeks of age and surviving progeny were quantified four weeks later (Fig. 1B, E), after which time point new cells are likely to persist for very long periods of time [45,46]. Newborn cells were identified as neurons by double labelling with neuronal marker, NeuN (Rbfox3, Fig. 1C). Among 3814 BrdU⁺ cells in 38 individuals, we detected only a single BrdU⁺/S100 β ⁺ astrocyte. We conclude that either astrogliogenesis is negligible in the DG of young HXB/BXH rats, or S100 β (the standard marker in mice in this case) is not expressed in newly-born astrocytes in these lines. Notably, over 90 % of BrdU-positive cells were neurons (Fig. 1F). Hence, we used the numbers of surviving BrdU-positive cells as an approximation of net neurogenesis within the HXB/BXH family. The majority of dividing cells in the DG are transient amplifying progenitors, which remain tightly clustered together (Fig. 1A–A’). We quantified the number of such clusters of proliferating cells, assuming that each cluster arises from an activated stem cell. The number of clusters tightly correlated to counts of individual cells (Pearson’s $r^2 = 0.92$; Fig. 1G). Such high correlation suggested that the numbers of proliferating cells were determined by the numbers of activated stem cells rather than differences in lineage progression or cell cycle dynamics in these animals, and pointed to a stereotyped pattern of lineage progression.

Fig. 1. Adult neurogenesis in the HXB/BXH family.

(A) Proliferating precursor cells were stained for Ki67, a marker of actively cycling cells. (A’–A’’) Proliferating cells occur in tightly packed clusters, which are likely to arise from single activated stem cells. (A’) High power view of two clusters indicated by arrows in (A). (A’’) An

example of a single large cluster of Ki67⁺ cells. (B) New cells in the DG were identified by DAB-immunostaining for BrdU 4 weeks after the last BrdU injection. (B') High power view of cells indicated by an arrow. (C) BrdU-positive cells (magenta, arrowhead) were identified as neurons by confocal microscopy after co-labelling with a neuronal marker, NeuN (green). (D-E) The number of proliferating (D) and surviving (E) cells in the DG of HXB/BXH, BN (red) and SHR (blue) strains. (F) Distribution of neuronal percentages among newborn cells across HXB/BXH family confirms that more than 90% of newborn cells are neurons. Box and whisker plot: centre line - median; upper and lower hinges - first and third quartiles; whiskers - highest and lowest values within 1.5 times the interquartile range outside hinges; dots - outlying data points. (G) Correlation between number of clusters and individual counts of proliferating cells. (H-I) Quantile-quantile plots of neurogenesis traits indicate normal distribution of strain means. (J) Rates of precursor cell proliferation are not predicting the number of surviving cells. r , Pearson's product-moment correlation coefficient. Scale bar, 100 and 20 μ m in A and B, 20 μ m in A', A'', B'' and C.

Proliferation and survival differed between 2- and 3-fold across the strains (Fig. 1D, E) and were normally distributed (Fig. 1H, I; BrdU: $W = 0.983$, $p = 0.88$; Ki67: $W = 0.976$, $p = 0.67$; Shapiro-Wilk test), consistent with the multigenic regulation of adult neurogenesis. Transgressive segregation was observed for both traits, indicating that genes with positive effect on neurogenesis were distributed between parents. The heritability was estimated as 0.41 and 0.29 for survival and proliferation, respectively. Interestingly, proliferation levels did not predict the rates of survival, as these measures did not correlated to each other ($r^2 = 0.026$; Fig. 1J). This finding implies that, under standard laboratory conditions, these two aspects of neurogenesis are influenced by largely separate sets of genes.

Shared QTL for neurogenesis and serum glucose

The search for genetic associations between adult neurogenesis and physiological traits was performed in several steps. First, we identified QTL for both neurogenic traits (Fig. 2A, B). We detected a suggestive QTL for net neurogenesis on chromosome 16 (LOD = 3.12, genome-wide corrected p value = 0.14) and a weak suggestive QTL for proliferation on chromosome 17 (LOD = 2.39, p = 0.52). Second, we identified phenotypes from the GeneNetwork database [34] that significantly correlated to both traits (Table 1). We then used these phenotypes as covariates in conditional QTL scans to screen for potential interactions at a genomic level. A substantial change in the LOD score after using another phenotype as a covariate indicates that genetic variation within a QTL may have pleiotropic effects on these two phenotypes [47]. Among pairs of correlating phenotypes, we detected only one such association: QTL mapping for net neurogenesis revealed a LOD drop below suggestive level to 0.43 after conditioning on serum glucose levels. Accordingly, an overlapping significant QTL for serum glucose was found on chromosome 16 (LOD = 5.13, p = 0.0065; Fig. 2C). This locus explained 37 % of the genetic variance in adult neurogenesis and 61 % of the genetic variance in serum glucose. The SHR allele was associated with an average decrease in BrdU cell numbers by 584 and in serum glucose by 0.656 mmol/L.

Table 1. Published phenotypes correlating to adult neurogenesis in HXB/BXH family.

Phenotype	<i>r</i>	N	<i>p</i> -value	ID
Net neurogenesis (BrdU⁺ cells)				
Glucose concentrations	0.57	24	0.0031	10003
Serum triglyceride concentrations	0.46	24	0.023	10014
Liver triglycerides	0.41	29	0.026	10119
Relative kidney weight	-0.40	28	0.034	10025
Serum chromogranin A levels	0.37	30	0.043	10132
Proliferation (Ki67⁺ cells)				
Adrenal phenyletanolamine-N-mythyltransferase	0.58	30	0.0006	10151
Adrenal dopamine	0.52	30	0.0031	10106
Adrenal epinephrine	0.47	30	0.0081	10105
Relative kidney weight	-0.45	28	0.015	10025
Insulin stimulated lipogenesis in epididymal fat	-0.44	31	0.012	10148
Adrenal chromogranin A levels	0.43	30	0.016	10133
Serum corticosterone levels after immobilization stress	-0.42	23	0.043	10064
Serum triglyceride concentrations, fed high fructose diet for 2 weeks	0.42	24	0.039	10016
Adrenal norepinephrine	0.40	30	0.029	10107
Urine calcium	0.39	28	0.041	10179
Basal lipogenesis in epididymal fat	-0.38	31	0.033	10146

All phenotypes were measured in male rats aged between 6 to 10 weeks. Details can be found in the GeneNetwork database (www.genenetwork.org). *r*, Pearson's product correlation coefficient; N, number of overlapping strains; ID, GeneNetwork identifier.

Fig. 2. *Tti2* is a candidate gene for common net neurogenesis and serum glucose quantitative trait locus (QTL).

(A-E) Whole-genome quantitative trait locus mapping for indicated traits. The genome-wide significant ($p < 0.05$) and suggestive ($p < 0.63$) thresholds of the logarithm of the odds (LOD) score (green and grey horizontal dashed lines, respectively) were calculated using permutations and corrected *p*-values are shown adjacent to the highest association in (A-C). QTL for net adult neurogenesis and a positively correlating phenotype, serum glucose level, have an overlapping pattern on chromosome 16. (D) An eigenvector of the two phenotypes (an *eigenphenotype*—the first principal component) was used to calculate a common confidence interval for the shared QTL (shaded areas in D and E). (E) *Tti2* gene, whose

genomic position is indicated by an orange triangle, has a local expression QTL within the eigenphenotype QTL confidence interval on chromosome 16 in all tested tissues. For clarity, in (D) and (E) only fragments of the chromosome 16 were plotted. (F) *Tti2* expression in the hippocampus or tissues relevant for regulation of glucose homeostasis, as indicated in the figure, is correlated to net neurogenesis and serum glucose. Colour specifies parental genotypes at the marker, which had the highest LOD score association with the eigenphenotype.

Finally, to derive a confidence interval for the joint survival-serum glucose QTL, we combined the variance from both traits using their first principal component, here referred to as an eigenphenotype. (Fig. 2D). The eigenphenotype QTL (LOD = 4.62, $p = 0.014$) spanned 4.2 Mb from genomic position 62.1 to 66.3 Mb and contained 11 protein-coding and 4 non-coding RNA genes.

***Tti2* is a candidate quantitative trait gene**

Genetic correlations between phenotypes can result from variation in shared regulatory genes or from linkage disequilibrium. In linkage disequilibrium, distinct genes governing each phenotype co-segregate together in the limited population of recombinant strains due to their physical proximity in the genome. To distinguish these scenarios and prioritise candidate genes for each phenotype, we used transcriptional profiles in tissues relevant for adult neurogenesis and metabolic regulation to cross-correlate with phenotypes and genetic markers. To that end, we profiled gene expression data from hippocampi of HXB/BXH and parental strains using microarrays. We also used published gene expression data sets from the soleus muscle, liver, perirenal fat, kidney, adrenal gland, left ventricle and aorta. Expression of only one single gene, Telo2-interacting protein 2 (*Tti2*), correlated significantly to both traits across all data sets (Fig. 2F). *Tti2* mRNA expression was linked to multi-tissue cis-eQTL mapped within the neurogenesis-glucose QTL on chromosome 16 (Fig. 2E). We thus carried out conditional mapping for neurogenesis and serum glucose using expression of *Tti2* as a covariate. Substantial drop in the LOD score between unconditioned and

conditioned scans strongly suggests that the QTL effect is mediated by the gene expression—consistent with the flow of causation from genes to phenotypes [47–49]. Using *Tti2* expression in the hippocampus as a covariate decreased the LOD score for adult neurogenesis by 2.34 (LOD = 0.78). To investigate the effect of *Tti2* expression in peripheral tissues on serum glucose mapping, we first summarised *Tti2* expression levels in these data sets as an eigengene (the first principal component). Using the *Tti2* eigengene as a covariate in QTL mapping decreased the LOD score for serum glucose by 2.76 (LOD = 2.37). The conditional LOD values for both phenotypes were below suggestive level. The SHR allele was associated with higher levels of *Tti2* mRNA, which we verified using quantitative RT-PCR in RNA isolated from the hippocampus, liver, muscle, kidney and pancreas (Table S1).

The allelic variation underlying a QTL can either change the expression level of a gene, or the function of its product by altering its structure. We inspected the genes located within the eigenphenotype QTL confidence interval for non-synonymous amino acid substitutions. Interestingly, only *Tti2* carried several missense mutations, including one at a highly conserved position, although none of the substitutions were predicted as damaging by Polyphen or SIFT (Table S2). Together, these data support *Tti2* as a causal candidate gene for the combined serum glucose and net neurogenesis QTL.

Reduced *Tti2* expression impairs adult neurogenesis and metabolic homeostasis

To evaluate whether expression of *Tti2* might be indeed causally linked to regulation of net adult neurogenesis and serum glucose, we derived heterozygous *Tti2* knockout rats on the SHR background. Using zinc finger nuclease, we introduced an 8-bp deletion in the first exon of *Tti2*, which resulted in a frameshift mutation, presumably generating a non-functional protein. Heterozygous male rats were compared to wild type littermates to assess consequences of the reduction of available *Tti2* for adult hippocampal neurogenesis and metabolism.

Net adult neurogenesis decreased by 21 % in the DG of 3-month-old SHR-*Tti2*^{+/-} compared to their wild-type SHR littermates (Fig. 3A; see Table 2 for detailed statistical

analysis). Concomitantly, heterozygous animals exhibited extensive alterations in metabolic parameters (Fig. 3; Fig. S1; Table 2 and 3). Heterozygous knock-out of *Tti2* resulted in lower plasma glucose and insulin levels (Fig. 3B-C). SHR-*Tti2*^{+/-} rats had also elevated plasma triglycerides (TG; Fig. 3D) and non-esterified fatty acids (NEFA; Fig. 3F) compared to SHR control. Changes in plasma lipid profile were accompanied by decrease of liver TG and cholesterol content (Fig. 3G-H). However, we did not observe an effect on total or HDL-bound fraction of plasma cholesterol (Fig. 3E, Fig. S1H). In SHR-*Tti2*^{+/-} animals we observed changes in body composition and organ sizes, including lipogenic tissues: they had smaller livers and epididymal fat deposits and increased perirenal fat weights (Fig. S1B-D). On the other hand, knock-out of *Tti2* did not affect the weight of brown adipose tissue (BAT; Fig. S1E). While the heterozygous rats were slightly larger compared to the control animals (Fig. S1A), this difference was not statistically significant.

Fig. 3. Knock-down of *Tti2* leads to decreased hippocampal neurogenesis and impaired glucose homeostasis.

(A-H) Three-months old heterozygous SHR-*Tti2*^{+/-} rats and wild type SHR-*Tti2*^{+/+} littermates (denoted as SHR) were assessed for the phenotypes indicated in the figure. (I-K) Glucose and lipid metabolism were measured *ex vivo* in diaphragm or epididymal adipose tissue in absence (basal conditions) or presence of 250 µU/mL insulin (stimulated condition) in the incubation media. (L) Basal and adrenaline-stimulated lipolysis were measured in the epididymal adipose tissue in absence or presence of 250 µg/ml adrenaline. Number of animals: (A) 18 rats of each genotype; (B-L) 8 SHR-*Tti2*^{+/-}, 6 SHR. *p* values were derived from Student's *t*-test (A-H) or linear mixed effect model (I-L). Full details of statistical analysis are in Tables 2 and 3. Abbreviations: NEFA, non-esterified free fatty acids; TG, triglycerides.

285 **Table 2. Statistical comparison of neurogenesis and metabolic traits between SHR-**
286 ***Tti2*^{+/-} rats and SHR wild type littermates.**

Phenotype	Unit	SHR	SHR- <i>Tti2</i> ^{+/-}	p value
Neurogenesis	BrdU+ cells/DG	4143 ± 79	3266 ± 55	0.04 *
Body and organ weights				
Body weight	g	296.47 ± 2.62	308.41 ± 1.37	0.12
Relative weight of epid. fat	g/100 g bwt	0.69 ± 0.003	0.63 ± 0.005	0.0049 *
Relative weight of perirenal fat	g/100 g bwt	0.52 ± 0.01	0.58 ± 0.01	0.022 *
Relative weight of BAT	g/100 g bwt	0.09 ± 0.002	0.08 ± 0.002	0.71
Relative weight of liver	g/100 g bwt	3.48 ± 0.01	3.3 ± 0.01	0.0061 *
Relative weight of heart	g/100 g bwt	0.36 ± 0.003	0.35 ± 0.001	0.14
Relative weight of kidney	g/100 g bwt	0.69 ± 0.004	0.67 ± 0.002	0.028 *
Blood chemistry				
Non-fasting glucose	mmol/l	7.53 ± 0.07	6.94 ± 0.03	0.0057 *
Insulin	nmol/l	0.38 ± 0.02	0.22 ± 0.005	9.6e-5 *
Serum TG	mmol/l	0.36 ± 0.01	0.43 ± 0.01	0.048 *
Total cholesterol	mmol/l	1.13 ± 0.03	1.07 ± 0.01	0.39
HDL-C	mmol/l	1.04 ± 0.03	0.97 ± 0.01	0.27
NEFA	mmol/l	0.50 ± 0.01	0.61 ± 0.01	3.8E-4 *
Adiponectin	□g/ml	2.63 ± 0.36	2.33 ± 0.35	0.589
Leptin	ng/ml	3.20 ± 0.23	3.31 ± 0.12	0.692
Tissue composition				
TG in liver	μmol/g	6.49 ± 0.24	4.7 ± 0.12	0.016 *
Cholesterol in liver	μmol/g	10.93 ± 0.16	9.27 ± 0.07	0.0014 *
TG in heart	μmol/g	2.29 ± 0.08	0.71 ± 0.03	2.8E-6 *
TG in kidney	μmol/g	5.33 ± 0.21	5.57 ± 0.12	0.69
TG in muscle	μmol/g	1.35 ± 0.09	1.29 ± 0.06	0.80
Glucose and lipid metabolism				
Glucose oxidation in BAT	nmol glucose/g/2h	441.78 ± 19.17	386.76 ± 14.01	0.39
Basal lipogenesis in BAT	nmol glucose/g/2h	294.37 ± 11.14	262.82 ± 6.63	0.34
Basal lipogenesis in epid. fat \$	nmol glucose/g/2h	481.05 ± 18.1	417 ± 8.62	0.80
Insulin-stimulated lipogenesis in epid. fat	nmol glucose/g/2h	717.14 ± 27.08	581.48 ± 23.12	0.23
Basal lipolysis in epid. fat	μmol NEFA/g	3.01 ± 0.05	3.51 ± 0.05	0.58
Adrenaline-stimulated lipolysis in epid. fat	μmol NEFA/g	6.09 ± 0.16	5.25 ± 0.13	0.15
Basal glycogenesis in diaphragm	nmol glucose/g/2h	892.26 ± 43.12	688.17 ± 30.06	0.37
Insulin-stimulated glycogenesis in diaphragm	nmol glucose/g/2h	1554.32 ± 35.04	701.84 ± 41.14	< 1E-4 *
Glucose oxidation in diaphragm	nmol glucose/g/2h	488.38 ± 20.66	343.98 ± 8.29	0.0042 *
Oxidative stress in the liver				
SOD activity	U/mg	0.16 ± 0.004	0.12 ± 0.003	0.026 *
GPx activity	μmol GSH/min/mg	293.14 ± 6.48	234.57 ± 5.26	0.021 *

GR activity	μmol NADPH/min/ mg	132.14 ± 4.51	112.57 ± 2.52	0.18
CAT activity	μmol H_2O_2 /min/mg	1260 ± 45.18	1522.14 ± 50.8	0.17
GSH/GSSG		39.64 ± 1.25	25.56 ± 0.97	0.0051*
GSH	$\mu\text{mol}/\text{mg}$	75.19 ± 1.18	72.94 ± 0.61	0.49
GSSG	$\mu\text{mol}/\text{mg}$	1.96 ± 0.07	3.15 ± 0.15	0.039 *
Conjugated dienes	nM/mg	35.29 ± 0.88	42.86 ± 0.71	0.027 *
TBARS	nM/mg	1.73 ± 0.06	1.36 ± 0.05	0.095

287

288 Table reports means $\pm$ standard errors of the mean. *p* values were derived from Student's *t*-
289 test or post-hoc Tukey test following two-way mixed effect model with an interaction between
290 genotype and stimulation as a fixed factor. Asterisks denote significance at $p < 0.05$.
291 Abbreviations: BAT, brown adipose tissue; CAT, catalase; HDL-C, high-density lipoprotein
292 bound cholesterol; epid., epididymal; GPx, glutathione peroxidase; GR, glutathione
293 reductase; GSH, glutathione; GSSG, oxidised glutathione; NEFA, non-esterified fatty acids;
294 SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances; TG,
295 triglycerides.

296

Table 3. Statistical analysis of response to insulin and adrenaline stimulation in tissues isolated from SHR-*Tti2*^{+/-} rats and SHR wild type littermates.

Phenotype	Term/Contrast	Statistic (d.f.)	p.value
Glycogenesis in diaphragm	Genotype	$\chi^2 (1) = 28.25$	1.1E-7 *
	Insulin	$\chi^2 (1) = 9.72$	0.0018 *
	Genotype:Insulin	$\chi^2 (1) = 11.03$	9E-4 *
	SHR:250 – SHR:0	$t(12) = 4.55$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(11) = 0.1$	1
Glucose oxidation in diaphragm	Genotype	$\chi^2 (1) = 7.82$	0.0052 *
	Insulin	$\chi^2 (1) = 1.34$	0.25
	Genotype:Insulin	$\chi^2 (1) = 3.07$	0.08
	SHR:250 – SHR:0	$t(12) = 2.08$	0.13
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = -0.27$	0.99
Lipogenesis in epididymal fat	Genotype	$\chi^2 (1) = 2.21$	0.14
	Insulin	$\chi^2 (1) = 34.59$	4.1E-9 *
	Genotype:Insulin	$\chi^2 (1) = 1.14$	0.29
	SHR:250 – SHR:0	$t(12) = 4.66$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = 3.75$	7.7E-4 *
Lipolysis in epididymal fat	Genotype	$\chi^2 (1) = 0.35$	0.56
	Adrenaline	$\chi^2 (1) = 62.01$	3.4E-15 *
	Genotype:Adrenaline	$\chi^2 (1) = 5.08$	0.024 *
	SHR:250 – SHR:0	$t(12) = 6.86$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = 4.48$	< 1E-4 *

Glucose and lipid metabolism were measured *ex vivo* in tissues isolated from SHR-*Tti2*^{+/-} rats and wild type SHR littermates under basal and induced conditions (without or with 250 μ U/ml insulin or 250 mg/ml adrenaline). The table shows results of two-way linear mixed effect models with Insulin, Genotype and Insulin:Genotype interaction or Adrenaline, Genotype and Adrenaline:Genotype as fixed effects and individual intercepts as a random effect. Statistical significance was evaluated by likelihood ratio test. Adjusted *p* values for comparisons within each genotype were obtained from *post-hoc* Tukey test for the interaction. Means and SEM for each group and the comparison between genotypes are shown in Table 2. Asterisks denote significance at *p* < 0.05; d.f., degrees of freedom.

Next, we investigated rates of glucose and lipid metabolism *ex vivo* in the skeletal muscle and adipose tissues from SHR-*Tti2*^{+/-} and SHR control rats under basal conditions and upon stimulation. In the diaphragm, knock-out of *Tti2* abolished stimulatory effect of insulin on both glucose incorporation into glycogen, and glucose oxidation (Fig. 3I-J, see Tables 2 and 3 for detailed statistical analysis). However, the basal rates of glucose oxidation and glycogenesis in heterozygous rats were not significantly different from intact littermates. Similarly, basal glucose oxidation in BAT was not different between genotypes (Fig. S1M). In contrast to glucose utilisation in the skeletal muscle, incorporation of glucose into lipids in epididymal adipose tissue was significantly stimulated by insulin in both genotypes (Fig. 3K) and we did not detect differences between heterozygous and control rats in basal nor stimulated condition. *De novo* lipogenesis also did not differ between SHR-*Tti2*^{+/-} and control rats in BAT (Fig. S1N). Furthermore, both SHR-*Tti2*^{+/-} and SHR animals upregulated lipolysis in presence of adrenaline (Fig. 3L). However, a significant interaction between genotype and adrenaline stimulation suggested different response to stimulation depending on the *Tti2* expression level.

Metabolic deregulation and dyslipidaemia are often associated with elevated oxidative stress. We thus examined the hallmarks of the hepatic oxidative status. Indeed, significantly upregulated conjugated dienes in livers from heterozygous rats compared to control littermates (Fig. 4A) suggested increased oxidative stress. Increased oxidation was indicated also by decreased ratio of reduced to oxidised glutathione (GSH/GSSG; Fig. 4G), mostly due to increased concentrations of oxidised glutathione (GSSG; Fig. 4H). In contrast, the content of thiobarbituric acid reactive substances (TBARS) showed a decreasing trend ($p = 0.095$; Fig. 4B). The changes in lipid peroxidation were accompanied by decreased activity of the antioxidant enzymes, superoxide dismutase (SOD; Fig. 4C) and glutathione peroxidase (GPx; Fig. 4E). Glutathione reductase (GR; Fig. 4F) and catalase (CAT, Fig. 4D) were not significantly different between SHR-*Tti2*^{+/-} and control littermates.

Fig. 4. Knock-down of *Tti2* alters oxidative status in the liver.

Livers extracts prepared from three-months old heterozygous SHR-*Tti2*^{+/-} rats (N = 7) and wild type SHR littermates (N = 7) were used to measure markers of oxidative stress as indicated in the figure. *p* values were derived from Student's *t*-test. Abbreviations: GSH, glutathione; GSSG, oxidised glutathione; TBARS, thiobarbituric acid reactive substances.

Together, these results indicate that lowering expression of functional full-length *Tti2* affected adult neurogenesis and metabolism, in particular glucose and insulin homeostasis, in agreement with *Tti2* being a causal gene underlying the joint neurogenesis and serum glucose QTL.

Gene expression profiles indicate glucose intolerance in SHR-*Tti2*^{+/-} rats

The *Tti2* protein, together with its binding partners, telomere maintenance 2 (Telo2) and *Tti1*, form a chaperone complex that assists folding and tertiary assembly of functional phosphatidylinositol 3-kinase-related kinases (PIKK): mammalian target of rapamycin (mTOR), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), suppressor of morphogenesis in genitalia (SMG1), transformation/transcription domain-associated protein (TRRAP) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) [50]. To get an insight into the molecular consequences of downregulation of *Tti2* expression, we performed transcriptional profiling of the hippocampus and three tissues essential for metabolic regulation in SHR-*Tti2*^{+/-} rats and their wild-type littermates. We detected 326 differentially expressed transcripts in the liver, 52 in the soleus muscle, 41 in the perirenal fat, and 10 in the hippocampus. In addition, the analysis confirmed reduction of *Tti2* mRNA in the heterozygous rats (Table S3). We next carried out functional annotations using Ingenuity Pathway Analysis (IPA), which infers shifts in activity of canonical pathways and potential upstream regulators from the direction and magnitude of gene expression changes using curated knowledge databases. Furthermore, IPA can link differentially expressed genes to downstream outcomes.

We first checked whether observed gene expression changes could be connected to altered activity of any of the PIKK. Among canonical pathways, IPA indicated enrichment for genes associated with ATM signalling in the liver, muscle, and fat, and with mTOR signalling in the muscle (Fig. S2B-D). Additionally, IPA predicted SMG1 as one of potential upstream regulators in the liver and hippocampus (File S1). Nevertheless, the majority of changes in gene expression were not directly connected to PIKK activity.

In agreement with the metabolic phenotype of SHR-*Tti2*^{+/-} rats, the transcriptional profile of the liver pointed to dysglycemia, specifically to decreased glucose tolerance and increased insulin resistance (Fig. 5A-B). IPA suggested four upstream regulators that could be linked to glucose intolerance: interleukin 6 (IL6), tuberous sclerosis complex 2 (Tsc2), peroxisome proliferator-activated receptor gamma coactivator 1-beta (Ppargc1b), and lysine (K)-specific histone demethylase 1A (Kdm1a) (Fig. S3). In addition, IPA indicated inhibition of insulin signalling as the most significant upstream regulator (File S2). The functional analysis also predicted a broad range of other metabolic changes, for example hepatic steatosis, decreased fatty acid metabolism and lipid synthesis (Fig. 5A, C; File S3). Even though only few differentially expressed genes were detected in the hippocampus of SHR-*Tti2*^{+/-} rats, these genes indicated decreased cellular homeostasis (Fig. 5A, D) and increased apoptosis. Very strong upregulation (24-times) of sphingosine1-phosphate (S1P) receptor 3 (S1pr3) and downregulation of alkaline ceramidase 2 (Acer2) suggested de-regulation of S1P signalling pathway in the hippocampus (Fig. S2A).

Fig. 5. Functional analysis of gene expression changes indicates insulin resistance and loss of cellular homeostasis in SHR-*Tti2*^{+/-} rats.

Differentially expressed genes between SHR-*Tti2*^{+/-} rats and wild type SHR littermates in the liver, muscle, perirenal adipose tissue and hippocampus were analysed using Ingenuity Pathway Analysis (IPA). IPA predicts activation or inhibition of functions, pathological processes and molecular pathways from the direction and magnitude of expression changes using curated databases. (A) Graph depicts activation (positive Z-score) or inhibition

(negative Z-score) of top functions and diseases in each of the analysed tissues. Full list of significantly affected functions can be found in File S3. (B-D) Edges in each network illustrate predicted relationships between upregulated (magenta) and downregulated (green) genes and downstream functions (centre nodes; orange, activating effect; blue, inhibitory effect). (E) Colour key. Asterisks in network graphs denote multi-protein complexes.

Human genomic variation links *TTI2* expression with genome-wide phenotype associations

Our results indicated that changes in expression levels of *Tti2* can affect both neural and metabolic homeostases. The majority of disease-associated variants in humans are likely to be involved in regulation of transcription [51,52]. Therefore, to link our findings to genomic variation in the human population, we searched the human eQTL catalogue (<https://www.ebi.ac.uk/eqtl/>) for variants associated with changes in the *TTI2* mRNA expression. We extracted 821 variants underlying 2177 eQTL ($p < 1e-4$) in 28 different tissues and cell types (File S4). Out of these, 214 variants were associated with the *TTI2* eQTL in at least 3 distinct tissue types (Fig. S4). The multi-tissue eQTL are more likely to represent true associations as well as being consequential for a wide range of phenotypes [16,17]. We next used all *TTI2* eQTL variants to query the GWAS databases (<https://www.ebi.ac.uk/gwas/>) for known phenotypic associations. We found 7 variants with reported associations to protein and stem cell factor blood concentrations, blood pressure and frontotemporal dementia (Table 4).

Table 4. Human genomic variants with overlapping associations to *TTI2* expression and phenotypes.

Variant ID	eQTL beta direction	eQTL data sets	Associated trait	Trait ID	GWAS p value	GWAS beta direction	Risk Frequency*
rs10094645	increase	Artery_Aorta, Muscle_Skeletal, Testis, Thyroid, Whole_Blood	blood protein measurement	EFO_0007937	4E-23	decrease	0.594
rs2732317	increase	Artery_Aorta, Testis, Thyroid, Whole_Blood	blood protein measurement	EFO_0007937	3E-77	decrease	0.612
rs2732260	increase	Monocyte	frontotemporal dementia, memory impairment	Orphanet_282 EFO_0001072	1E-6	NA	0.03
rs2732259	increase	Esophagus_Muscularis, Muscle_Skeletal, Testis, Whole_Blood	hypoxanthine measurement	EFO_0010500	7E-6	increase	0.619*
rs6996562	increase	Artery_Aorta, Testis, Whole_Blood	pulse pressure measurement	EFO_0005763	2E-10	increase	0.473
rs7845722	increase	Artery_Aorta, Muscle_Skeletal, Testis, Whole_Blood	pulse pressure measurement	EFO_0005763	1E-9	increase	0.4
rs1568119	decrease	Monocyte	stem cell factor measurement	EFO_0008291	1E-7	increase	0.08*

821 variants linked to *TTI2* eQTLs ($p < 1E-4$) were used to search human genome-wide association studies (GWAS) catalogue. *Data sets* column lists tissues and cell types in which significant eQTLs were detected for a given variant. For GWAS studies for which risk frequencies were not reported, we included variant frequencies from phase 3 1000 Genomes Project combined population (denoted with asterisks).

Discussion

In this study we used unbiased systems genetics methods to i) discover a number of metabolic and endocrine genetic correlates of the two critical parameters of adult hippocampal neurogenesis—precursor cell proliferation and net neurogenesis; and ii) identify *Tti2* as a molecular link between brain cellular plasticity and peripheral metabolism.

The HXB/BXH family is well-suited to discover genetic physiological correlates of cognitive endophenotypes

The HXB/BXH family of 30 members has only modest statistical power to detect QTL, as the majority of loci have only small effects on phenotypes and variants behind a substantial part of heritability fall below stringent significance levels. Nonetheless, the chief advantage of recombinant inbred strains is their suitability to measure the tendency of traits to co-segregate [44]. Because each inbred line can supply an indefinite number of isogenic individuals, multiple phenotypes can be measured in the same genotype, the collected data are cumulative and comparable across time and laboratories. Use of separate cohorts of animals to assess different phenotypes precludes intra-individual correlations and ensures that any associations between traits are due to shared genetic variation. Genetic correlations, therefore, may suggest the presence of allelic variants with pleiotropic effects on correlating phenotypes. Here we showed that, under basic laboratory conditions, precursor cell proliferation and the final outcome of adult neurogenesis—numbers of surviving neurons—are under the control of largely distinct sets of genes. Accordingly, each of these traits correlated to non-overlapping collections of metabolic and endocrine parameters. Because adult neurogenesis—although a complex process in itself—represents one specific aspect of brain plasticity, these correlations advance our understanding of interactions between global metabolic features and cognition. Here we proceeded to dissect in-depth the correlation between serum glucose and net neurogenesis, which could both be mapped to a common overlapping QTL. The majority of discovered correlations, however, could not be explained by such a strong genetic association, in agreement with the polygenic nature of

quantitative traits. Other methods, such as gene co-expression analyses, have the potential to integrate available data and elucidate mechanisms underlying remaining relationships [32].

***Tti2* as a pleiotropic gene regulating net neurogenesis and metabolic homeostasis**

Using transcriptional profiles from peripheral tissues and the hippocampus as intermediate phenotypes between complex physiological outcomes and genomic variation we were able to narrow down the 'serum glucose-neurogenesis' QTL interval to the *Tti2* candidate gene. *Tti2*, together with its binding partners, *Tti1* and telomere maintenance 2 (*Telo2*) protein, form the Triple T (TTT) complex [53], which associates with a number of molecular chaperones, including Hsp90, Hsp70, Hsp40, and the R2TP/prefoldin-like complex [54,55]. TTT binds to nascent peptides of PI3K-related protein kinases (PIKK) and thereby acts as a specialised chaperone and a critical regulator of PIKK abundance in mammalian and yeast cells [53,55–58]. In mammals, the PIKK family consists of ATM, ATR, mTOR, TRAPP, SMG1, and DNA-PKcs. These proteins play strategic roles in multiple cellular functions, such as genome stability, DNA repair, regulation of gene and protein expression, nonsense-mediated RNA decay, cell growth and cell cycle progression, and regulation of responses to nutrient availability [59–62]. All PIKK are also an important part of stress responses [63].

In our present study, we generated a heterozygous SHR-*Tti2*^{+/-} line carrying a frame-shift mutation in the N-terminal domain of *Tti2*. Mutational screens in yeast produced viable cells only when truncations were located at the very end of the C-terminus of *Tti2* [64], hence we predicted that this modification results in a non-functional protein. Our aim was to mirror the eQTL effect and reduce the amount of available *Tti2* rather than remove it completely. The SHR background had been chosen because the SHR allele is associated with higher *Tti2* expression. The mutation halved the *Tti2* mRNA content in heterozygous rats compared to the wild-type littermates, as established by RNA sequencing. Although antibodies recognising rodent *Tti2* were not available, experiments in yeast have suggested that the *Tti2* protein abundance is directly correlated to mRNA expression [53]. SHR-*Tti2*^{+/-} rats had

similar body weights, gross morphology and general cage behaviour as the wild-type littermates. However, reducing *Tti2* expression to 50% led to a reduction of the number of new neurons in the DG, a concomitant lowering of serum glucose and insulin concentrations, and to hallmarks of insulin resistance in skeletal muscles. Metabolic alterations in SHR-*Tti2*^{+/-} rats went beyond glucose homeostasis: we also observed changes in lipid metabolism and elevated oxidative stress in the liver. Together, these findings support *Tti2* as a causal gene within the joint 'serum glucose-neurogenesis' QTL.

Expression of *Tti2* correlated negatively to adult neurogenesis and serum glucose concentrations in the HXB/BXH family, yet in the SHR rats with only one functional copy of the *Tti2* gene we saw a further decrease of each trait value. This disparity would imply that the SHR allele is associated with decrease of the Tti2 protein function despite higher *Tti2* mRNA abundance. The SHR allele carries six amino-acid substitutions, including Glu247Asp within the highly conserved Tti2 family super-helical central domain (conservation score 1.0; see Supplementary Table 1) and Lys198Glu at a moderately conserved residue (score 0.57) in the N-terminal portion of the protein. Although all substitutions were scored as benign by prediction algorithms SIFT and PolyPhen, it cannot be excluded that they have an impact on protein stability or interactions with any of the binding partners. Higher mRNA expression could evolve independently or as a compensation of reduced function. For example, in the duplicated maize genome, the number of copies of genes encoding TTT complex members and PIKK have all reverted to one, suggesting evolutionary pressure to maintain gene dosage balance [65].

Transcriptome profiling of SHR-*Tti2*^{+/-} rats revealed extensive gene expression changes in the liver, and to a lesser degree in the skeletal muscle, perirenal fat and hippocampus compared to SHR wild type littermates. Liver, together with skeletal muscle and adipose tissue are decisive organs in maintenance of glucose homeostasis and hence development of insulin resistance [66]. Functional analysis of differentially expressed genes in the liver identified networks of genes and potential regulators whose activation and inhibition could explain insulin resistance and dysglycemia in the heterozygous animals. We also recorded

significant upregulation of *Insr* in the muscle, which IPA interpreted as consistent with hypoglycaemia and insulin resistant diabetes (File S3).

We also used IPA to predict which upstream regulators could be activated or inhibited in a manner consistent with observed gene expression changes. The vast majority of differentially expressed genes were not linked to PIKK activity. Thus far only PIKK peptides were identified as clients of the TTT complex despite attempts to capture other target proteins [64]. Therefore it is unlikely that another, yet unknown, pathway contributes to the observed phenotypes. Depletion of *Tti2* destabilises all PIKK proteins and impairs nuclear localisation of ATM, ATR and TRRAP, but does not affect their mRNA abundance [53,64]. Notwithstanding the lack of direct evidence, reduction of *Tti2* expression in SHR-*Tti2*^{+/-} rats may destabilise the TTT complex and consequently impair signalling of PIKK. It has been reported that reduced PIKK signalling due to tissue-specific targeting of selected genes in the mouse led to impaired adipogenesis (reduced fat deposits), insulin resistance with lower insulin-stimulated glucose transport, reduced antilipolytic effects of insulin (increased NEFA levels), and ectopic fat accumulation [67–71]. These results are similar to metabolic disturbances observed in SHR-*Tti2*^{+/-} rats suggesting involvement of the same molecular pathways. Our data also do not allow differentiating whether all or only some of the PIKK are compromised in the SHR-*Tti2*^{+/-} rats. Destabilisation of the TTT complex has strongest effects on ATM and ATR protein levels and to a lesser extent other PIKK [53,58,64,72]. Interestingly, in SHR-*Tti2*^{+/-} rats IPA detected enrichment of differentially expressed genes related to ATM signalling in the liver, muscle and fat and mTOR signalling in the muscle. While these results do not imply that other PIKK were not affected, ATM might be the most sensitive to *Tti2* downregulation also in rats used in our study.

Pleiotropy occurs when a single genomic variation, or more broadly a change in a function of a single gene, has multiple consequences at the phenotypic level [9]. Because metabolic diseases can, to some extent, be modified by lifestyle interventions in order to prevent or dampen cognitive decline, but genes cannot, it is clinically crucial to understand which correlations between metabolic and cognitive phenotypes arise from genetic predisposition

due to pleiotropic genes. Because we used targeted mutagenesis at the *Tti2* locus rather than tissue specific approaches to confirm association with target phenotypes, we cannot exclude that *Tti2* affects neurogenesis through circulating metabolites or hormones. Correlations between traits in the absence of genetic variation indicate indirect effects [10]. Hippocampal plasticity and neurogenesis are intricately related to nutrient availability and insulin and insulin-like growth factor 1 (IGF1) signalling [73–76]. Glucose is the primary energy source for the nervous system. Hyperglycemia and insulin resistance are detrimental to the brain and negatively influence adult hippocampal neurogenesis [77–80]. In addition, caloric restriction, which lowers plasma insulin and glucose levels, resulted in increased survival of new neurons and higher net neurogenesis [81]. These associations hint that, as such, the lower serum glucose measured in SHR-*Tti2*^{+/-} rats may not necessarily lead to lower neuronal survival. In the HXB/BXH family, neurogenesis correlated positively to serum insulin (Pearson's $r = 0.35$, $p = 0.09$). However, we did not detect any consistent associations with measures of insulin resistance, suggesting that peripheral insulin resistance is also unlikely a sole cause of neurogenesis impairment in SHR-*Tti2*^{+/-} rats. Furthermore, transcriptional profiling of the hippocampus from heterozygous animals did not indicate brain insulin resistance. Metabolic tissues in heterozygous rats also manifested deregulated lipid metabolism. Higher levels of circulating triglycerides and free fatty acids could further contribute to disrupted glucose metabolism and neurogenesis. For example, high fat diets, which increase circulating plasma lipids and lipid peroxidation, have been documented as detrimental to neurogenesis and cognition [82,83].

The support in favour of direct effects of *Tti2* reduction on neurogenesis comes from the severe neural deficits in individuals carrying loss-of-function mutations in *TTI2* in the absence of serious metabolic insufficiencies. In humans, homozygous and compound heterozygous loss-of-function mutations in *TTI2* cause microcephaly, severe intellectual disability, dysmorphic facial features, short stature, speech and movement disorders, and skeletal deformations [72,84–86]. Similar abnormalities were observed in children carrying *TELO2* mutations [87,88]. Particularly, failures of DNA repair pathways downstream of the TTT

complex have detrimental effects on development and maintenance of the central nervous system. Recessive mutations in ATM cause ataxia telangiectasia, a disease characterised by progressive neuronal degeneration [89,90]; while loss of ATR leads to Seckel syndrome characterised by postnatal dwarfism, microcephaly, intrauterine growth defects, and mental retardation [91]. ATM, ATR and DNA-PKcs are essential to preserving the genome integrity during replication [92] and thus their function is particularly important in dividing precursor cells in the course of neurogenesis [93], also in the adult hippocampus [94]. Knock-out of ATM or ATR in mice has detrimental effects on brain development, with pronounced loss of hippocampal neurons [95]. ATM-deficient mice have abnormally increased rates of proliferation with concomitantly lowered survival of new neurons [94]. In human neural stem cells, ATM suppresses excessive retrotransposition [96], the process which contributes to neural diversity and plasticity during hippocampus development, and then in the adult stem cells [97].

mTOR also plays multiple roles in the development and function of the brain [98], including maintenance of neural progenitor cell pools. During embryonic development, conditional knockout of mTOR in neural stem cells dramatically reduced their proliferation thereby reducing production of postmitotic neurons and brain size [99]. Similarly, inhibition of mTORC1 signalling in the neural stem cells in the neonatal subventricular zone (SVZ) of the lateral ventricle, which also harbours a population of neural stem cells that persist throughout life, reduced generation of transient amplifying precursor cells and thus decreased the abundance of their differentiated progeny [100]. In addition, transient systemic inhibition of the mTOR pathway by rapamycin in early postnatal life resulted in abnormal proliferation, reduced progenitor cell numbers, and eventually decreased the volume of the adult dentate gyrus [101].

ATM and mTOR are both downstream targets of insulin and IGF1 signalling [89]. Insulin and IGF1 provide trophic signals that can both stimulate and inhibit proliferation and survival of adult precursor cells *in vivo* [74,102–107]. Insulin is also expressed directly in neuronal progenitors [108]. The massive upregulation of S1pr3 and downregulation of Acer2 in the

hippocampus of SHR-*Tti2*^{+/-} rats suggested changes in the sphingosine-1-phosphate (S1P) signalling pathway, which is implicated in the control of cell death and survival, as well as synaptic plasticity via interactions with multiple cellular signalling cascades [109–112]. Interestingly, S1pr3 potentiates IGF1 signalling [113], and cross-links with the mTOR-AKT nutrient sensing pathway [114]. Although our analysis of differentially expressed genes did not suggest changes in PIKK activity in the hippocampus of heterozygous animals, the precursor cells and immature neurons are only a minor fraction of the entire hippocampus and therefore we might not have captured genes affected specifically in these cells. For example, Ka and colleagues [99] found that in the developing cerebral cortex mTOR signalling was detected mostly in the radial neural stem cells, the principal precursor cells of the developing central nervous system, with very low activity in the postmitotic neuronal layers. In the early postnatal and adult SVZ, mTOR activity was also concentrated in actively proliferating transient amplifying progenitor cells [100,115]. All told, the interwoven relationships between peripheral metabolism, insulin and PIKK signalling pathways point to complex responses to intracellular deficits in PIKK and extracellular signals in the brain of SHR-*Tti2*^{+/-} rats, and lend support for truly pleiotropic roles of *Tti2* in the regulation of glucose homeostasis and structural brain plasticity. Future development of tissue- and cell-specific conditional knockouts shall help to decipher the consequences of *Tti2* depletion for these functions independently of each other.

Limitations

In our study we used only male rats. This decision was dictated by compatibility with existing data, as the vast majority of published HXB/BXH phenotypes were measured in young male rats to avoid inter-individual variation due to oestrous cycle. Further experiments will show whether any of the identified associations interacts with sex.

Conclusion

Understanding of the molecular events by which a genomic variation leads to physiological consequences for the organism across many functions provides a foundation for effective precision medicine. Our study exemplifies the power of rodent genetic reference populations not only to identify associations between phenotypes that are difficult or even impossible to assess in humans, but also to give insights into the cell biology behind these associations. Our experiments showed that manipulating the abundance of a single component of the protein folding machinery had relatively subtle yet significant effects on a broad range of phenotypes. Mining human data sets revealed more than 800 genomic variants that are linked to *TTI2* expression, seven of which refer to associations with protein and blood stem cell factor concentrations, blood pressure, and frontotemporal dementia. Given the dose-dependent effects of *Tti2* on adult hippocampal neurogenesis and glucose homeostasis, we speculate that human variants that affect *TTI2* expression or function may also have quantitative effects on these phenotypes.

Acknowledgments

The authors would like to thank Karel Vales, Michaela Radostna, Hana Brozka, Jan-Hendrik Claasen, Perla Leal-Galicia, Tara L. Walker, and Sara Zocher for assistance with perfusions; Anna Rumiantseva for help with histological staining; Vladimir Landa for microinjecting fertilised ova with the ZFN construct; Olena Oliarnyk for oxidative stress analysis; Edwin Cuppen, Marieke Simonis, Kathrin Saar, and Oliver Hummel for SHR genomic variants and genotype information.

Funding

This work was supported by DFG (KE 615/9-1) (ANG, GK), Energi (ANG, GK) and basic TUD and DZNE institutional funding (ANG, RWO, KSF, GK). MP and HM were supported by the Ministry of Health of the Czech Republic under the conceptual development of research

639 organizations program (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001
 640 (HM) and by the Academic Premium (Praemium academiae) (AP1502) (MP); AS was
 641 supported by Czech Health Research Council (AZV) grant 17-30833A and Czech Science
 642 Foundation (GACR) projects 19-03016S and 20-00939S.
 643

Materials and Methods

Animals

Brown Norway BN-Lx/Cub, spontaneously hypertensive SHR/OlaIpcv (referred to as BN and SHR, respectively) and 30 HXB/BXH recombinant inbred strains, as well as SHR-*Tti2*^{+/-} knockout heterozygous rats used in the current study were housed in an air-conditioned animal facility at the Institute of Physiology, Czech Academy of Sciences. HXB/BXH strains are inbred for more than 80 generations. Animals were maintained on a 12 h light/dark cycle in the standard laboratory cages provided with standard laboratory chow and water *ad libitum*. To assess survival of new-born cells in the dentate gyrus, 10-week-old animals were given 3 daily intraperitoneal injections of 50 mg/kg bromodeoxyuridine (BrdU; Sigma) and perfused 28 days later. We studied 5–9 male rats from each strain derived from at least 3 independent litters (total 243 rats). To isolate tissues for RNA and protein isolation, rats were anaesthetised with ketamine and decapitated. Tissues were placed in RNA later (microarray) or snap frozen in liquid nitrogen. For the microarray analysis, one male and one female 10-week-old rat from each parental and HXB/BXH strains were used (total 64 rats). Biochemical, metabolic and hemodynamic phenotypes were assessed in 3-month-old non-fasted male SHR-*Tti2*^{+/-} rats and their wild-type littermates (N = 8 per strain). All experiments were performed in agreement with the Animal Protection Law of the Czech Republic and were approved by the Ethics Committee of the Institute of Physiology, Czech Academy of Sciences, Prague (Permit number: 66/2014).

Generation of *Tti2* knockout SHR rats.

Tti2 knockout rats were generated by microinjecting fertilized ova of SHR rats with the ZFN (Zinc Finger Nuclease) construct from Sigma-Aldrich. The construct was designed to target the first exon using the following sequence of ZFN binding (capital letters) and cutting site (small letters): TCTGACCCGGATCCAAGCaccaagGGTGGGTGGCAGGGC. DNA samples isolated from 452 rats born after microinjection with ZFN construct were amplified

using primers flanking the target sequence: ZFN F: 5'-TACACTGTGATTGGCTGGGA-3' and ZFN R: 5'-GGCGCAGTGGAGTGATC-3'. Altogether 4 positive animals were detected. An SHR-*Tti2*^{tm1}/lpcv line no.14 (referred to as SHR-*Tti2*^{+/-}) with an 8 bp deletion (NM_001013883.1(*Tti2*):c.243_250delCGAGATCC; on the protein level: NP_001013905.1:p.Glu82Glyfs) has been selected for further analyses. The heterozygous founder was crossed with SHR and F1 rats were intercrossed. SHR-*Tti2*^{+/-} heterozygotes were selected for breeding and phenotyping while their wild type littermates were used as controls.

Histology

Histology was carried out using standard procedures [45]. Rats were deeply anaesthetised with a mixture of ketamine/xylazine and intracardially perfused with 0.9% NaCl, followed by ice-cold 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB), pH 7.4. The brains were removed, post-fixed overnight in 4 % PFA and equilibrated in 30 % w/v sucrose in 0.1 M phosphate buffer. 40 µm frozen coronal sections were cut on a sliding microtome (Leica) and stored in a cryo-protective solution (25 % ethylene glycol, 25 % glycerol in 0.1 M PB) at -20 °C.

For immunohistochemistry, every sixth section was washed in Tris-buffered saline (TBS) and pretreated in 3 % H₂O₂ and 10 % methanol in TBS for 15 min. After several washes in TBS and NaCl, DNA was denatured with 2.5 M HCl for 30 min at 37 °C. Multiple washes in phosphate-buffered saline (PBS) were performed between each subsequent step. The sections were incubated in a blocking solution containing 10 % donkey serum and 0.3 % Triton-X100 in PBS for 1 h and then with primary antibodies (rat anti-BrdU, 1:500, OBT0030, AbD Serotec; or rabbit anti-Ki67, 1:500, NCL-Ki67p, Novocastra) diluted in the blocking solution for 48 – 72 h at 4 °C. Sections were incubated for 2.5 h with biotinylated secondary antibodies (1:500, Jackson ImmunoResearch) diluted in the blocking solution containing 3 % donkey serum. Immunocomplexes were detected using the Vectastain Elite ABC kit (Vector Laboratories) and 0.02 % diaminobenzidine (D5905, Sigma) enhanced with NiCl₂. After

mounting in 0.1 M PB onto gelatine-coated glass slides, the sections were air dried, cleared in the alcohol gradient series, and coverslipped with Entellan New (Merck).

Cells were quantified using a simplified optical fractionator method as discussed before [Kempermann 2003 PMID: 12466205]. BrdU positive cells were quantified along the rostro-caudal axis in the granule cell layer (GCL) and subgranular zone (SGZ) defined as a two-cell wide band below the GCL. Ki67 cells were quantified in the three-cell wide zone below the GCL and in the inner third of the GCL. Clusters of cells were defined as at least three cells not further apart than two-cell diameter. The cells in the uppermost focal plane were ignored to avoid oversampling errors. The counts from left and right sides of the DG in each sample were averaged and multiplied by 6 (section sampling interval) to obtain total numbers of newborn (BrdU) or proliferating (Ki67) cells in per dentate gyrus.

To assess the identity of BrdU-positive cells and estimate the range of neuronal and astrocyte survival across the HXB/BXH family, sections from three randomly selected individuals from each parental strain and one from each HXB/BXH member were processed for fluorescent staining with BrdU, NeuN and S100 β . Every twelfth section was washed twice in NaCl, pretreated in 2 M HCl for 30 min at 37 $^{\circ}$ C and washed in PBS. After blocking, sections were incubated for 48 h at 4 $^{\circ}$ C with primary antibodies (rat anti-BrdU, 1:500, OBT Serotec; mouse anti-NeuN, 1:200, MAB377, Millipore; rabbit anti-S100 β , 1:2000, Ab41548, Abcam) diluted in the blocking solution. After washing in PBS, sections were incubated for 4 h with secondary antibodies (anti-rat Cy3, anti-mouse DyLight 488, anti-rabbit Cy5, 1:500, Jackson ImmunoResearch) diluted in the blocking solution, washed in PBS and mounted onto glass slides using fluorescence mounting medium Aqua-Poly/Mount (Polysciences). 100 randomly selected BrdU-positive cells from each animal along the rostro-caudal axis of the DG were imaged at 400 $\times$ magnification with spectral confocal microscope (TCS SP2, Leica) and examined for NeuN and S100 β immunoreactivity.

Microarray analysis

Hippocampi were dissected from brains stored in RNA later and RNA was isolated using RNA STAT-60 kit (Tel-Test Inc). RNA was purified using standard sodium acetate-ethanol precipitation method. RNA purity and concentration was evaluated using 260/280 nm absorbance ratio and the quality was checked using Agilent Bioanalyzer 2100 prior to hybridisation. Samples were hybridised onto GeneChip Rat Exon 1.0 ST microarrays (Affymetrix) using manufacturers protocols.

Along with the hippocampus gene expression data, we analysed published data sets from parental and 29 recombinant inbred strains from adrenal gland, liver, skeletal muscle, perirenal fat, kidney, aorta and ventricle [37,38,40]. These data sets consisted of microarray analysis on Affymetrix Rat230_2 (muscle, liver, aorta and ventricle) and RAE230A (adrenal gland, fat and kidney) chips. Unprocessed microarray expression data were retrieved from ArrayExpress, (www.ebi.ac.uk/arrayexpress; adrenal gland, E-TABM-457; liver, E-MTAB-323; muscle, E-TABM-458; fat and kidney, E-AFMX-7; aorta, E-MTAB-322; left ventricle, E-MIMR-222).

Probes from each data set were assembled into probesets mapped to Ensemble gene identifiers from Rnor_5.0 rat genome release using Version 10 custom cell definition files from the Brain Array (University of Michigan) website [116]. Probes that mapped to regions containing insertions, deletions or single nucleotide polymorphisms in the SHR/Ola or BN-Lx/Cub strains compared to the reference genome [43] were removed prior the analysis to avoid spurious linkage due to differential hybridisation. Probesets which after filtering contained less than 3 probes were removed. Gene expression summaries were derived using robust multichip average (RMA) algorithm [117] in the R Affy package [118].

Heritability

In repeated sampling of isogenic individuals, the variance observed within the genotype can be attributed to environmental influences, whereas differences between strains are primarily due to differences in genotypes. Thus, we defined narrow sense heritability as the

intraclass correlation coefficient obtained from a mixed linear model employing restricted maximum likelihood approach using function *lmer* from lme4 R package [119,120].

QTL mapping

Phenotype QTL were calculated using strain means for surviving (BrdU⁺) and proliferating (Ki67⁺) cells in the DG as well as for phenotypes correlating to neurogenesis traits. Expression QTL (eQTL) were calculated for all genes in each data set. Marker regression against SNP-based genotype markers mapped to Rnor_5.0 genome assembly with 2049 unique strain distribution patterns in 29 HXB/BXH strains [121] was performed using the QTLReaper program [122], which reports likelihood ratio statistic (LRS) score at each marker. LRS was converted to logarithm of odds ratio (LOD) by dividing by 4.61, where $LOD \approx -\log_{10}(p)$. Empirical genome-wide significance of linkage was determined by a permutation test as previously described [37]. Genome wide significance was defined as the 95th percentile of the maximum LOD score and less stringent suggestive threshold as the 37th percentile, which on average yields one false positive per genome scan [123,124]. The 95 % confidence intervals for QTL were calculated in R/qtl using Bayesian method [125]. Traits with overlapping QTL were summarised as their first principal component, an eigenphenotype (adult neurogenesis and serum glucose) or eigengene (*Tti2* expression), using WGCNA R package [126]. eQTL were defined as local when position of a QTL mapped within 10 Mb from the physical location of the gene [37]. Conditional genome scans were carried out in R/qtl as described previously [47–49] to establish relationships between genomic loci, gene expression and phenotypes using function *scanone* with parameter *addcovar*. The gene was considered causal when the LOD score of the phenotype QTL fell below suggestive level after conditioning on its expression. Analysis of mutations of candidate genes was performed using tools in Rat Genome Database [127]. All genomic positions were mapped to Rnor_5.0 genome assembly.

RNA isolation and quantitative PCR

RNA was isolated using RNeasy Mini Kit (Qiagen) following manufacturer's instructions. Genomic DNA was removed by on-column DNase digestion. Frozen tissues were homogenised in QIAzol with TissueRuptor (Qiagen). cDNA was synthesised with SuperScript II reverse transcriptase (Invitrogen) using oligo(dT) primers and 1 µg of total RNA. Quantitative PCR was performed using SYBR Green PCR kit (Qiagen) on cDNA corresponding to 25 ng of total RNA using the following conditions: 95 °C for 15 min, and 40 cycles at 94 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s. Gene-specific primer pairs were designed using Primer3 software [128]. Dissociation analysis from 55 °C to 90 °C of the end product was performed to ensure specificity. Cycle of threshold (CT) values were normalised to the GAPDH reference to calculate the relative level of gene expression on the log₂ scale (Δ CT). Mean Δ CT values from BN rats were then subtracted from each sample Δ CT to obtain $\Delta\Delta$ CT values.

RNA sequencing and analysis

RNA was isolated as described above from the frozen hippocampus, liver, soleus muscle and perirenal adipose tissue samples isolated from SHR-Tti2^{+/-} rats and wild-type SHR-Tti2^{+/+} littermates. RNA integrity was confirmed using BioAnalyzer (Agilent Technologies, Germany). Sequencing libraries were prepared using NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® from 300 ng of total RNA, with mRNA enrichment by poly-dT pull down using the NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB) according to the manufacturer's instructions. Samples were then directly subjected to the workflow for strand-specific RNA-Seq library preparation (Ultra II Directional RNA Library Prep, NEB). For ligation custom adaptors were used (Adaptor-Oligo 1: 5'-ACA CTC TTT CCC TAC ACG ACG CTC TTC CGA TCT-3', Adaptor-Oligo 2: 5'-P-GAT CGG AAG AGC ACA CGT CTG AAC TCC AGT CAC-3'). After ligation, adapters were depleted by an XP bead purification (Beckman Coulter) adding the beads solution in a ratio of 1:0.9. Dual indexing was done during the following PCR enrichment (12 cycles, 65 °C) using custom amplification primers

carrying the same sequence for i7 and i5 index (Primer 1: AAT GAT ACG GCG ACC ACC GAG ATC TAC AC NNNNNNNN ACA TCT TTC CCT ACA CGA CGC TCT TCC GAT CT, Primer 2: CAA GCA GAA GAC GGC ATA CGA GAT NNNNNNNN GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC T). After two more XP bead purifications (1:0.9), libraries were quantified using the Fragment Analyzer (Agilent). For Illumina flowcell production, samples were equimolarly pooled and sequenced 75bp single-end on multiple Illumina NextSeq 500 flowcells, aiming for approximately 30 million sequencing reads per sample.

Expression levels of individual transcripts were estimated by kallisto (ver. 0.46.1) [129] using Ensembl cDNA database (release 97) [130] as a reference. The software was executed with sequence-based bias correction, 100 bootstrap samples, an average fragment length of 200 bp and standard deviation set to 20. Differential expression analysis was carried out using an R package sleuth (ver. 0.30.0) [131]. A single outlier hippocampus sample was identified by examining a principal component projection and removed from further analysis. Samples obtained from each tissue were used to fit independent statistical models, with genotype as a single covariate, using 5 or 4 replicates per genotype. Statistical significances of changes in transcript abundances were computed using a Wald test. A 10 % FDR (false discovery rate) cut-off and an absolute value of fold change of 1.5 were used to identify differentially expressed genes. Functional enrichment analysis was performed with Ingenuity Pathway Analysis software (IPA; Qiagen) at default settings [132].

Basal and insulin stimulated glycogen synthesis in skeletal muscle.

For measurement of insulin stimulated incorporation of glucose into glycogen, diaphragmatic muscles were incubated for 2 h in 95% O₂ + 5% CO₂ in Krebs-Ringer bicarbonate buffer, pH 7.4, containing 0.1 µCi/ml of ¹⁴C-U glucose, 5 mmol/L of unlabelled glucose, and 2.5 mg/ml of bovine serum albumin (Armour, Fraction V), with or without 250 µU/ml insulin. Glycogen was extracted, and basal and insulin stimulated incorporation of glucose into glycogen was determined.

Glucose utilization in isolated epididymal adipose tissue and brown adipose tissue.

Distal parts of epididymal adipose tissue or interscapular brown adipose tissue were rapidly dissected and incubated for 2 hours in Krebs-Ringer bicarbonate buffer with 5 mmol/L glucose, 0.1 μ Ci 14 C-U-glucose/mL (UVVR, Prague, Czech Republic) and 2% bovine serum albumin, gaseous phase 95% O₂ and 5% CO₂ in the presence (250 μ U/mL) or absence of insulin in incubation media. All incubations were performed at 37 °C in sealed vials in a shaking water bath. Then we estimated incorporation of 14 C-glucose into neutral lipids. Briefly, adipose tissue was removed from incubation medium, rinsed in saline, and immediately put into chloroform. The pieces of tissue were dissolved using a Teflon pestle homogenizer, methanol was added (chloroform:methanol 2:1), and lipids were extracted at 4 °C overnight. The remaining tissue was removed, KH₂PO₄ was added and a clear extract was taken for further analysis. An aliquot was evaporated, reconstituted in scintillation liquid, and the radioactivity measured by scintillation counting. Incremental glucose utilization was calculated as the difference between the insulin stimulated and basal incorporation of glucose into neutral lipids.

Lipolysis in isolated epididymal adipose tissue.

For measurement of basal and adrenaline stimulated lipolysis, the distal parts of epididymal adipose tissue were incubated in Krebs-Ringer phosphate buffer containing 3 % bovine serum albumin (Armour, Fraction V) at 37 °C, pH 7.4 with or without adrenaline (0.25 μ g/ml). The tissue was incubated for 2 hours and the concentrations of NEFA and glycerol in the medium were determined.

Tissue triglyceride and cholesterol measurements.

For determination of triglycerides in liver, gastrocnemius muscle, kidney, and heart, tissues were powdered under liquid N₂ and extracted for 16 hours in chloroform:methanol, after which 2 % KH₂PO₄ was added and the solution was centrifuged. The organic phase was removed and evaporated under N₂. The resulting pellet was dissolved in isopropyl

alcohol, and triglyceride and cholesterol concentrations were determined by enzymatic assay (Pliva-Lachema, Brno, Czech Republic).

Biochemical analyses.

Blood glucose levels were measured by the glucose oxidase assay (Pliva-Lachema, Brno, Czech Republic) using tail vein blood drawn into 5 % trichloroacetic acid and promptly centrifuged. NEFA levels were determined using an acyl-CoA oxidase-based colorimetric kit (Roche Diagnostics GmbH, Mannheim, Germany). Serum triglyceride and cholesterol concentrations were measured by standard enzymatic methods (Pliva-Lachema, Brno, Czech Republic). Glycerol was determined using an analytical kit from Sigma. Serum insulin concentrations were determined using a rat insulin ELISA kit (Mercodia, Uppsala, Sweden).

Parameters of oxidative stress.

Activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and glutathione reductase (GR) were analysed using Cayman Chemicals assay kits (MI, USA) according to manufacturer's instructions. Catalase (CAT) activity measurement was based on the ability of H₂O₂ to produce with ammonium molybdate a colour complex detected spectrophotometrically. The level of reduced glutathione (GSH) was determined in the reaction of SH-groups using Ellman reagent. The level of reduced (GSH) and oxidized (GSSG) form of glutathione was determined by high-performance liquid chromatography method with fluorescent detection according to HPLC diagnostic kit (Chromsystems, Munich, Germany). Lipoperoxidation products were assessed by the levels of thiobarbituric acid reactive substances (TBARS) determined by assaying the reaction with thiobarbituric acid. The levels of conjugated dienes were analysed by extraction in the media (heptane:isopropanol = 2:1) and measured spectrophotometrically in heptane's layer.

Statistical analysis

Statistical analyses were performed in R [133]. Normality of distribution of strain means for neurogenesis phenotypes was checked using Shapiro-Wilk test. Differences between groups

were tested using Student's *t*-test or ANOVA followed by Tukey or Dunnett's post hoc test. Responses to insulin were analysed with a two-way linear mixed effect models using the lme4 R package [120]. Genotype, insulin treatment and interaction between genotype and treatment were used as fixed effects and individual intercepts were used as a random effect. Significance of main terms was evaluated by likelihood ratio test using function *Anova* from the car package [134], followed by Tukey post hoc test using multcomp package [135]. Values are represented as means +/- standard error of the mean. Plots were generated using the ggplot2 package [136].

Data

Neurogenesis data was deposited in the HXB/BXH Published Phenotypes Database at the GeneNetwork (www.genenetwork.org) under Record IDs: 10193 (BrdU⁺ cells), 10194 (Ki67⁺ cells), 10195 (clusters of Ki67⁺ cells). Hippocampal gene expression dataset was deposited at GeneNetwork under GN Accession GN231. RNA sequencing of SHR and SHR-Tti2^{+/-} rats was deposited to Gene Ontology Omnibus under the accession number GSE160361.

References

1. Panza F, Solfrizzi V, Logroscino G, Maggi S, Santamato A, Seripa D, et al. Current epidemiological approaches to the metabolic-cognitive syndrome. *Journal of Alzheimer's Disease*. IOS Press; 2012. doi:10.3233/JAD-2012-111496
2. Watanabe K, Stringer S, Frei O, Umičević Mirkov M, de Leeuw C, Polderman TJC, et al. A global overview of pleiotropy and genetic architecture in complex traits. *Nat Genet*. 2019;51: 1339–1348. doi:10.1038/s41588-019-0481-0
3. Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. *EBioMedicine*. 2020;59. doi:10.1016/j.ebiom.2020.102954
4. Nikpay M, Mohammadzadeh S. Phenome-wide screening for traits causally associated with the risk of coronary artery disease. *J Hum Genet*. 2020;65: 371–380. doi:10.1038/s10038-019-0716-z
5. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet*. 2013;92: 197–209. doi:10.1016/j.ajhg.2013.01.001
6. Zhang T, Goodman M, Zhu F, Healy B, Carruthers R, Chitnis T, et al. Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. *Neurol Neuroimmunol neuroinflammation*. 2020;7. doi:10.1212/NXI.0000000000000864
7. Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of dementia: Observational and Mendelian randomisation studies in 1 million individuals. *Epidemiol Psychiatr Sci*. 2020;29. doi:10.1017/S2045796020000347
8. Mollon J, Curran JE, Mathias SR, Knowles EEM, Carlisle P, Fox PT, et al. Neurocognitive impairment in type 2 diabetes: evidence for shared genetic aetiology. *Diabetologia*. 2020;63: 977–986. doi:10.1007/s00125-020-05101-y
9. Stearns FW. One hundred years of pleiotropy: A retrospective. *Genetics*. Genetics; 2010. pp. 767–773. doi:10.1534/genetics.110.122549
10. Geiler-Samerotte KA, Li S, Lazaris C, Taylor A, Ziv N, Ramjeawan C, et al. Extent and context dependence of pleiotropy revealed by high-throughput single-cell phenotyping. *PLoS Biol*. 2020;18. doi:10.1371/journal.pbio.3000836
11. White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, et al. XGenome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. *Cell*. 2013;154: 452. doi:10.1016/j.cell.2013.06.022
12. McGuigan K, Collet JM, McGraw EA, Ye YH, Allen SL, Chenoweth SF, et al. The nature and extent of mutational pleiotropy in gene expression of male *Drosophila serrata*. *Genetics*. 2014;196: 911–921. doi:10.1534/genetics.114.161232
13. Wagner GP, Zhang J. The pleiotropic structure of the genotype-phenotype map: The evolvability of complex organisms. *Nature Reviews Genetics*. *Nat Rev Genet*; 2011. pp. 204–213. doi:10.1038/nrg2949
14. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, et al. Abundant pleiotropy in human complex diseases and traits. *Am J Hum Genet*. 2011;89: 607–618. doi:10.1016/j.ajhg.2011.10.004
15. Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and interpretation of shared genetic influences on 42 human traits. *Nat Genet*. 2016;48: 709–717. doi:10.1038/ng.3570
16. Shikov AE, Skitchenko RK, Predeus A V., Barbitoff YA. Phenome-wide functional dissection of pleiotropic effects highlights key molecular pathways for human complex traits. *Sci Rep*. 2020;10: 1–10. doi:10.1038/s41598-020-58040-4
17. Jordan DM, Verbanck M, Do R. HOPS: A quantitative score reveals pervasive horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of human traits and diseases. *Genome Biol*. 2019;20. doi:10.1186/s13059-019-1844-7
18. Toda T, Gage FH. Review: adult neurogenesis contributes to hippocampal plasticity.

- 948 Cell and Tissue Research. Springer Verlag; 2018. pp. 693–709. doi:10.1007/s00441-
949 017-2735-4
- 950 19. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, et al.
951 XDynamic of hippocampal neurogenesis in adult humans. *Cell*. 2013;153: 1219.
952 doi:10.1016/j.cell.2013.05.002
- 953 20. Knobloch M, Jessberger S. Metabolism and neurogenesis. *Current Opinion in*
954 *Neurobiology*. Elsevier Ltd; 2017. pp. 45–52. doi:10.1016/j.conb.2016.11.006
- 955 21. Kempermann G, Chesler EJ, Lu L, Williams RW, Gage FH. Natural variation and
956 genetic covariance in adult hippocampal neurogenesis. *Proc Natl Acad Sci U S A*.
957 2006;103: 780–785. doi:10.1073/pnas.0510291103
- 958 22. Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the
959 dentate gyrus of adult mice. *Proc Natl Acad Sci U S A*. 1997;94: 10409–10414.
960 doi:10.1073/pnas.94.19.10409
- 961 23. Printz MP, Jirout M, Jaworski R, Alemayehu A, Kren V. Invited review: HXB/BXH rat
962 recombinant inbred strain platform: A newly enhanced tool for cardiovascular,
963 behavioral, and developmental genetics and genomics. *Journal of Applied Physiology*.
964 American Physiological Society; 2003. pp. 2510–2522.
965 doi:10.1152/jappphysiol.00064.2003
- 966 24. Liska F, Peterkova R, Peterka M, Landa V, Zóadek V, Mlejnek P, et al. Targeting of
967 the Plzf gene in the rat by transcription activator-like Effector nuclease results in
968 caudal regression syndrome in spontaneously hypertensive rats. *PLoS One*. 2016;11.
969 doi:10.1371/journal.pone.0164206
- 970 25. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with
971 spontaneous hypertension. *Metabolism*. 1988;37: 303–305. doi:10.1016/0026-
972 0495(88)90127-8
- 973 26. Pravenec M, Zídek V, Landa V, Šimáková M, Mlejnek P, Kazdová L, et al. Genetic
974 Analysis of “Metabolic Syndrome” in the Spontaneously Hypertensive Rat. *Physiol*
975 *Res*. 2004;53: 15–22. Available: <http://www.biomed.cas.cz/physiolres>
- 976 27. Pravenec M. Use of rat genomics for investigating the metabolic syndrome. *Methods*
977 *Mol Biol*. 2010;597: 415–426. doi:10.1007/978-1-60327-389-3_28
- 978 28. Terry A V., Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and
979 nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats.
980 *Neuroscience*. 2000;101: 357–368. doi:10.1016/S0306-4522(00)00377-8
- 981 29. Grünblatt E, Bartl J, Iuhos D-I, Knezovic A, Trkulja V, Riederer P, et al.
982 Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied
983 by brain insulin receptor dysfunction. *J Mol Psychiatry*. 2015;3. doi:10.1186/s40303-
984 015-0012-6
- 985 30. Sabbatini M, Strocchi P, Vitaioli L, Amenta F. The hippocampus in spontaneously
986 hypertensive rats: A quantitative microanatomical study. *Neuroscience*. 2000;100:
987 251–258. doi:10.1016/S0306-4522(00)00297-9
- 988 31. Mignini F, Vitaioli L, Sabbatini M, Tomassoni D, Amenta F. The cerebral cortex of
989 spontaneously hypertensive rats: A quantitative microanatomical study. *Clinical and*
990 *Experimental Hypertension*. Clin Exp Hypertens; 2004. pp. 287–303.
991 doi:10.1081/CEH-120034135
- 992 32. Tabakoff B, Smith H, Vanderlinden LA, Hoffman PL, Saba LM. Networking in Biology:
993 The Hybrid Rat Diversity Panel. *Methods in Molecular Biology*. Humana Press Inc.;
994 2019. pp. 213–231. doi:10.1007/978-1-4939-9581-3_10
- 995 33. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al.
996 Comment: The FAIR Guiding Principles for scientific data management and
997 stewardship. *Sci Data*. 2016;3: 1–9. doi:10.1038/sdata.2016.18
- 998 34. Mulligan MK, Mozhui K, Prins P, Williams RW. Genenetwork: A toolbox for systems
999 genetics. *Methods in Molecular Biology*. Humana Press Inc.; 2017. pp. 75–120.
1000 doi:10.1007/978-1-4939-6427-7_4
- 1001 35. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J, et al.
1002 Progress and prospects in rat genetics: A community view. *Nature Genetics*. Nat

- Genet; 2008. pp. 516–522. doi:10.1038/ng.147
36. Morrissey C, Grieve IC, Heinig M, Atanur S, Petretto E, Pravenec M, et al. Integrated genomic approaches to identification of candidate genes underlying metabolic and cardiovascular phenotypes in the spontaneously hypertensive rat. *Physiol Genomics*. 2011;43: 1207–1218. doi:10.1152/physiolgenomics.00210.2010
37. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, et al. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. *Nat Genet*. 2005;37: 243–253. doi:10.1038/ng1522
38. Petretto E, Mangion J, Dickens NJ, Cook SA, Kumaran MK, Lu H, et al. Heritability and tissue specificity of expression quantitative trait loci. *PLoS Genet*. 2006;2: 1625–1633. doi:10.1371/journal.pgen.0020172
39. Adriaens ME, Lodder EM, Moreno-Moral A, Silhavý J, Heinig M, Glinge C, et al. Systems genetics approaches in rat identify novel genes and gene networks associated with cardiac conduction. *J Am Heart Assoc*. 2018;7. doi:10.1161/JAHA.118.009243
40. Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, Lu H, et al. A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. *Nature*. 2010;467: 460–464. doi:10.1038/nature09386
41. Pravenec M, Churchill PC, Churchill MC, Viklicky O, Kazdova L, Aitman TJ, et al. Identification of renal Cd36 as a determinant of blood pressure and risk for hypertension. *Nat Genet*. 2008;40: 952–954. doi:10.1038/ng.164
42. Atanur SS, Birol I, Guryev V, Hirst M, Hummel O, Morrissey C, et al. The genome sequence of the spontaneously hypertensive rat: Analysis and functional significance. *Genome Res*. 2010;20: 791–803. doi:10.1101/gr.103499.109
43. Simonis M, Atanur SS, Linsen S, Guryev V, Ruzius FP, Game L, et al. Genetic basis of transcriptome differences between the founder strains of the rat HXB/BXH recombinant inbred panel. *Genome Biol*. 2012;13. doi:10.1186/gb-2012-13-4-r31
44. Nadeau JH, Burrage LC, Restivo J, Pao YH, Churchill G, Hoit BD. Pleiotropy, homeostasis, and functional networks based on assays of cardiovascular traits in genetically randomized populations. *Genome Res*. 2003;13: 2082–2091. doi:10.1101/gr.1186603
45. Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. *Development*. 2003. pp. 391–399. doi:10.1242/dev.00203
46. Zocher S, Schilling S, Grzyb AN, Adusumilli VS, Lopes JB, Günther S, et al. Early-life environmental enrichment generates persistent individualized behavior in mice. *Sci Adv*. 2020;6. doi:10.1126/sciadv.abb1478
47. Li R, Tsaih SW, Shockley K, Stylianou IM, Wergedal J, Paigen B, et al. Structural model analysis of multiple quantitative traits. *PLoS Genet*. 2006;2: 1046–1057. doi:10.1371/journal.pgen.0020114
48. Leduc MS, Blair RH, Verdugo RA, Tsaih SW, Walsh K, Churchill GA, et al. Using bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an MRL/MpJ x SM/J intercross. *J Lipid Res*. 2012;53: 1163–1175. doi:10.1194/jlr.M025833
49. Leduc MS, Hageman RS, Verdugo RA, Tsaih SW, Walsh K, Churchill GA, et al. Integration of QTL and bioinformatic tools to identify candidate genes for triglycerides in mice. *J Lipid Res*. 2011;52: 1672–1682. doi:10.1194/jlr.M011130
50. Sugimoto K. Branching the Tel2 pathway for exact fit on phosphatidylinositol 3-kinase-related kinases. *Current Genetics*. Springer Verlag; 2018. pp. 965–970. doi:10.1007/s00294-018-0817-9
51. Ardlie KG, DeLuca DS, Segrè A V., Sullivan TJ, Young TR, Gelfand ET, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. *Science* (80-). 2015;348: 648–660. doi:10.1126/science.1262110
52. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS.

- Gibson G, editor. PLoS Genet. 2010;6: e1000888. doi:10.1371/journal.pgen.1000888
53. Hurov KE, Cotta-Ramusino C, Elledge SJ. A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. Genes Dev. 2010;24: 1939–1950. doi:10.1101/gad.1934210
54. Hořejší Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. Mol Cell. 2010;39: 839–850. doi:10.1016/j.molcel.2010.08.037
55. Takai H, Xie Y, De Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. Genes Dev. 2010;24: 2019–2030. doi:10.1101/gad.1956410
56. Stirling PC, Bloom MS, Solanki-Patil T, Smith S, Sipahimalani P, Li Z, et al. The complete spectrum of yeast chromosome instability genes identifies candidate cin cancer genes and functional roles for astra complex components. PLoS Genet. 2011;7. doi:10.1371/journal.pgen.1002057
57. Takai H, Wang RC, Takai KK, Yang H, de Lange T. Tel2 Regulates the Stability of PI3K-Related Protein Kinases. Cell. 2007;131: 1248–1259. doi:10.1016/j.cell.2007.10.052
58. Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, et al. Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly. J Biol Chem. 2010;285: 20109–20116. doi:10.1074/jbc.M110.121699
59. Yamashita A. Role of SMG-1-mediated Upf1 phosphorylation in mammalian nonsense-mediated mRNA decay. Genes to Cells. Genes Cells; 2013. pp. 161–175. doi:10.1111/gtc.12033
60. Cimprich KA, Cortez D. ATR: An essential regulator of genome integrity. Nature Reviews Molecular Cell Biology. Nat Rev Mol Cell Biol; 2008. pp. 616–627. doi:10.1038/nrm2450
61. Shimobayashi M, Hall MN. Making new contacts: The mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15: 155–162. doi:10.1038/nrm3757
62. Murr R, Vaissière T, Sawan C, Shukla V, Herceg Z. Orchestration of chromatin-based processes: Mind the TRRAP. Oncogene. Oncogene; 2007. pp. 5358–5372. doi:10.1038/sj.onc.1210605
63. Abraham RT. PI 3-kinase related kinases: “Big” players in stress-induced signaling pathways. DNA Repair. Elsevier; 2004. pp. 883–887. doi:10.1016/j.dnarep.2004.04.002
64. Hoffman KS, Duennwald ML, Karagiannis J, Genereaux J, McCarton AS, Brandl CJ. Saccharomyces cerevisiae Tti2 regulates PIKK proteins and stress response. G3 Genes, Genomes, Genet. 2016;6: 1649–1659. doi:10.1534/g3.116.029520
65. Garcia N, Messing J. TTT and PIKK complex genes reverted to single copy following polyploidization and retain function despite massive retrotransposition in maize. Front Plant Sci. 2017;8. doi:10.3389/fpls.2017.01723
66. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. American Physiological Society; 2018. pp. 2133–2223. doi:10.1152/physrev.00063.2017
67. Shan T, Zhang P, Jiang Q, Xiong Y, Wang Y, Kuang S. Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice. Diabetologia. 2016;59: 1995–2004. doi:10.1007/s00125-016-4006-4
68. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC. Muscle-Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and Enhances Basal Glycogen Synthase Activity. Mol Cell Biol. 2008;28: 61–70. doi:10.1128/mcb.01405-07
69. Kumar A, Lawrence JC, Jung DY, Ko HJ, Keller SR, Kim JK, et al. Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes. 2010;59: 1397–1406. doi:10.2337/db09-1061
70. Takagi M, Uno H, Nishi R, Sugimoto M, Hasegawa S, Piao J, et al. ATM Regulates

- 1113 Adipocyte Differentiation and Contributes to Glucose Homeostasis. *Cell Rep.* 2015;10:
1114 957–967. doi:10.1016/j.celrep.2015.01.027
- 1115 71. Mao Z, Zhang W. Role of mTOR in glucose and lipid metabolism. *International Journal*
1116 *of Molecular Sciences.* MDPI AG; 2018. doi:10.3390/ijms19072043
- 1117 72. Langouët M, Saadi A, Rieunier G, Moutton S, Siquier-Pernet K, Fernet M, et al.
1118 Mutation in TTI2 reveals a role for triple T complex in human brain development. *Hum*
1119 *Mutat.* 2013;34: 1472–1476. doi:10.1002/humu.22399
- 1120 73. Mainardi M, Fusco S, Grassi C. Modulation of hippocampal neural plasticity by
1121 glucose-related signaling. *Neural Plasticity.* Hindawi Publishing Corporation; 2015.
1122 doi:10.1155/2015/657928
- 1123 74. Fernandez AM, Torres-Alemán I. The many faces of insulin-like peptide signalling in
1124 the brain. *Nature Reviews Neuroscience.* Nat Rev Neurosci; 2012. pp. 225–239.
1125 doi:10.1038/nrn3209
- 1126 75. van Praag X, Fleshner M, Schwartz MW, Mattson MP. Exercise, energy intake,
1127 glucose homeostasis, and the brain. *J Neurosci.* 2014;34: 15139–15149.
1128 doi:10.1523/JNEUROSCI.2814-14.2014
- 1129 76. Rafalski VA, Brunet A. Energy metabolism in adult neural stem cell fate. *Progress in*
1130 *Neurobiology.* Prog Neurobiol; 2011. pp. 182–203.
1131 doi:10.1016/j.pneurobio.2010.10.007
- 1132 77. Marissal-Arvy N, Campas MN, Semont A, Ducroix-Crepy C, Beauvieux MC, Brossaud
1133 J, et al. Insulin treatment partially prevents cognitive and hippocampal alterations as
1134 well as glucocorticoid dysregulation in early-onset insulin-deficient diabetic rats.
1135 *Psychoneuroendocrinology.* 2018;93: 72–81. doi:10.1016/j.psyneuen.2018.04.016
- 1136 78. Sun P, Knezovic A, Parlak M, Cuber J, Karabeg M, Deckert J, et al. Long-Term Effects
1137 of Intracerebroventricular Streptozotocin Treatment on Adult Neurogenesis in the Rat
1138 Hippocampus. *Curr Alzheimer Res.* 2015;12: 772–784.
1139 doi:10.2174/1567205012666150710112147
- 1140 79. Stranahan AM, Arumugam T V., Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes
1141 impairs hippocampal function through glucocorticoid-mediated effects on new and
1142 mature neurons. *Nat Neurosci.* 2008;11: 309–317. doi:10.1038/nn2055
- 1143 80. Zhang WJ, Tan YF, Yue JTY, Vranic M, Wojtowicz JM. Impairment of hippocampal
1144 neurogenesis in streptozotocin-treated diabetic rats. *Acta Neurol Scand.* 2008;117:
1145 205–210. doi:10.1111/j.1600-0404.2007.00928.x
- 1146 81. Lee J, Seroogy KB, Mattson MP. Dietary restriction enhances neurotrophin expression
1147 and neurogenesis in the hippocampus of adult mice. *J Neurochem.* 2002;80: 539–547.
1148 doi:10.1046/j.0022-3042.2001.00747.x
- 1149 82. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs
1150 neurogenesis: Involvement of lipid peroxidation and brain-derived neurotrophic factor.
1151 *Neurosci Lett.* 2010;482: 235–239. doi:10.1016/j.neulet.2010.07.046
- 1152 83. Klein C, Jonas W, Iggena D, Empl L, Rivalan M, Wiedmer P, et al. Exercise prevents
1153 high-fat diet-induced impairment of flexible memory expression in the water maze and
1154 modulates adult hippocampal neurogenesis in mice. *Neurobiol Learn Mem.* 2016;131:
1155 26–35. doi:10.1016/j.nlm.2016.03.002
- 1156 84. Ziegler A, Bader P, McWalter K, Douglas G, Houdayer C, Bris C, et al. Confirmation
1157 that variants in TTI2 are responsible for autosomal recessive intellectual disability. *Clin*
1158 *Genet.* 2019;96: 354–358. doi:10.1111/cge.13603
- 1159 85. Wang R, Han S, Liu H, Khan A, Xiaerbaty H, Yu X, et al. Novel compound
1160 heterozygous mutations in tti2 cause syndromic intellectual disability in a chinese
1161 family. *Front Genet.* 2019;10. doi:10.3389/fgene.2019.01060
- 1162 86. Picher-Martel V, Labrie Y, Rivest S, Lace B, Chrestian N. Whole-exome sequencing
1163 identifies homozygous mutation in TTI2 in a child with primary microcephaly: A case
1164 report. *BMC Neurol.* 2020;20. doi:10.1186/s12883-020-01643-1
- 1165 87. You J, Sobreira NL, Gable DL, Jurgens J, Grange DK, Belnap N, et al. A Syndromic
1166 Intellectual Disability Disorder Caused by Variants in TELO2, a Gene Encoding a
1167 Component of the TTT Complex. *Am J Hum Genet.* 2016;98: 909–918.

- doi:10.1016/j.ajhg.2016.03.014
88. Moosa S, Altmüller J, Lyngbye T, Christensen R, Li Y, Nürnberg P, et al. Novel compound heterozygous mutations in *TELO2* in a patient with severe expression of You-Hoover-Fong syndrome. *Mol Genet Genomic Med*. 2017;5: 580–584. doi:10.1002/mgg3.287
89. Choy KR, Watters DJ. Neurodegeneration in ataxia-telangiectasia: Multiple roles of ATM kinase in cellular homeostasis. *Developmental Dynamics*. John Wiley and Sons Inc.; 2018. pp. 33–46. doi:10.1002/dvdy.24522
90. Shiloh Y, Ziv Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. *Nature Reviews Molecular Cell Biology*. Nat Rev Mol Cell Biol; 2013. pp. 197–210. doi:10.1038/nrm3546
91. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. *Nat Genet*. 2003;33: 497–501. doi:10.1038/ng1129
92. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. *Nature Reviews Molecular Cell Biology*. Nature Publishing Group; 2008. pp. 297–308. doi:10.1038/nrm2351
93. Enriquez-Rios V, Dumitrache LC, Downing SM, Li Y, Brown EJ, Russell HR, et al. DNA-PKcs, ATM, and ATR interplay maintains genome integrity during neurogenesis. *J Neurosci*. 2017;37: 893–905. doi:10.1523/JNEUROSCI.4213-15.2016
94. Allen DM, Van Praag H, Ray J, Weaver Z, Winrow CJ, Carter TA, et al. Ataxia telangiectasia mutated is essential during adult neurogenesis. *Genes Dev*. 2001;15: 554–566. doi:10.1101/gad.869001
95. Lee Y, Shull ERP, Frappart PO, Katyal S, Enriquez-Rios V, Zhao J, et al. ATR maintains select progenitors during nervous system development. *EMBO J*. 2012;31: 1177–1189. doi:10.1038/emboj.2011.493
96. Coufal NG, Garcia-Perez JL, Peng GE, Marchetto MCN, Muotri AR, Mu Y, et al. Ataxia telangiectasia mutated (ATM) modulates long interspersed element-1 (L1) retrotransposition in human neural stem cells. *Proc Natl Acad Sci U S A*. 2011;108: 20382–20387. doi:10.1073/pnas.1100273108
97. Singer T, McConnell MJ, Marchetto MCN, Coufal NG, Gage FH. LINE-1 retrotransposons: Mediators of somatic variation in neuronal genomes? *Trends Neurosci*. 2010;33: 345–354. doi:10.1016/j.tins.2010.04.001
98. Garza-Lombó C, Gonshebat ME. Mammalian target of rapamycin: Its role in early neural development and in adult and aged brain function. *Frontiers in Cellular Neuroscience*. Frontiers Media S.A.; 2016. doi:10.3389/fncel.2016.00157
99. Ka M, Condorelli G, Woodgett JR, Kim WY. mTOR regulates brain morphogenesis by mediating GSK3 signaling. *Dev*. 2014;141: 4076–4086. doi:10.1242/dev.108282
100. Hartman NW, Lin T V., Zhang L, Paquetel GE, Feliciano DM, Bordey A. MTORC1 Targets the Translational Repressor 4E-BP2, but Not S6 Kinase 1/2, to Regulate Neural Stem Cell Self-Renewal InVivo. *Cell Rep*. 2013;5: 433–444. doi:10.1016/j.celrep.2013.09.017
101. Raman L, Kong X, Kernie SG. Pharmacological inhibition of the mTOR pathway impairs hippocampal development in mice. *Neurosci Lett*. 2013;541: 9–14. doi:10.1016/j.neulet.2013.01.045
102. Åberg MAI, Åberg ND, Palmer TD, Alborn AM, Carlsson-Skewir C, Bang P, et al. IGF-I has a direct proliferative effect in adult hippocampal progenitor cells. *Mol Cell Neurosci*. 2003;24: 23–40. doi:10.1016/S1044-7431(03)00082-4
103. Trejo JL, Carro E, Torres-Alemán I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. *J Neurosci*. 2001;21: 1628–1634. doi:10.1523/jneurosci.21-05-01628.2001
104. Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. *Neuroscience*. 2001;107: 603–613. doi:10.1016/S0306-4522(01)00378-5

- 1223 105. Cheng CM, Cohen M, Tseng V, Bondy CA. Endogenous IGF1 enhances cell survival
1224 in the postnatal dentate gyrus. *J Neurosci Res.* 2001;64: 341–347.
1225 doi:10.1002/jnr.1084
- 1226 106. Agis-Balboa RC, Fischer A. Generating new neurons to circumvent your fears: The
1227 role of IGF signaling. *Cellular and Molecular Life Sciences. Cell Mol Life Sci*; 2014. pp.
1228 21–42. doi:10.1007/s00018-013-1316-2
- 1229 107. Chaker Z, Aïd S, Berry H, Holzenberger M. Suppression of IGF-I signals in neural
1230 stem cells enhances neurogenesis and olfactory function during aging. *Aging Cell.*
1231 2015;14: 847–856. doi:10.1111/acer.12365
- 1232 108. Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, et al.
1233 Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the
1234 olfactory bulb. *EMBO Mol Med.* 2011;3: 742–754. doi:10.1002/emmm.201100177
- 1235 109. Van Brocklyn JR, Williams JB. The control of the balance between ceramide and
1236 sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of
1237 cell survival and death. *Comparative Biochemistry and Physiology - B Biochemistry
1238 and Molecular Biology.* Elsevier Inc.; 2012. pp. 26–36. doi:10.1016/j.cbpb.2012.05.006
- 1239 110. Ghasemi R, Dargahi L, Ahmadiani A. Integrated sphingosine-1 phosphate signaling in
1240 the central nervous system: From physiological equilibrium to pathological damage.
1241 *Pharmacological Research. Academic Press*; 2016. pp. 156–164.
1242 doi:10.1016/j.phrs.2015.11.006
- 1243 111. Karunakaran I, van Echten-Deckert G. Sphingosine 1-phosphate – A double edged
1244 sword in the brain. *Biochimica et Biophysica Acta - Biomembranes.* Elsevier B.V.;
1245 2017. pp. 1573–1582. doi:10.1016/j.bbamem.2017.03.008
- 1246 112. Kanno T, Nishizaki T, Proia RL, Kajimoto T, Jahangeer S, Okada T, et al. Regulation
1247 of synaptic strength by sphingosine 1-phosphate in the hippocampus. *Neuroscience.*
1248 2010;171: 973–980. doi:10.1016/j.neuroscience.2010.10.021
- 1249 113. Martin JL, Lin MZ, McGowan EM, Baxter RC. Potentiation of growth factor signaling by
1250 insulin-like growth factor-binding protein-3 in breast epithelial cells requires
1251 sphingosine kinase activity. *J Biol Chem.* 2009;284: 25542–25552.
1252 doi:10.1074/jbc.M109.007120
- 1253 114. Jęsko H, Stępień A, Lukiw WJ, Strosznajder RP. The Cross-Talk Between
1254 Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and
1255 Neurodegeneration. *Molecular Neurobiology. Humana Press Inc.*; 2019. pp. 3501–
1256 3521. doi:10.1007/s12035-018-1286-3
- 1257 115. Paliouras GN, Hamilton LK, Aumont A, Joppé SE, Barnabé-Heider F, Fernandes KJL.
1258 Mammalian target of rapamycin signaling is a key regulator of the transit-amplifying
1259 progenitor pool in the adult and aging forebrain. *J Neurosci.* 2012;32: 15012–15026.
1260 doi:10.1523/JNEUROSCI.2248-12.2012
- 1261 116. Sandberg R, Larsson O. Improved precision and accuracy for microarrays using
1262 updated probe set definitions. *BMC Bioinformatics.* 2007;8. doi:10.1186/1471-2105-8-
1263 48
- 1264 117. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.
1265 Exploration, normalization, and summaries of high density oligonucleotide array probe
1266 level data. *Biostatistics.* 2003;4: 249–264. doi:10.1093/biostatistics/4.2.249
- 1267 118. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - Analysis of Affymetrix GeneChip
1268 data at the probe level. *Bioinformatics.* 2004;20: 307–315.
1269 doi:10.1093/bioinformatics/btg405
- 1270 119. Mhyre TR, Chesler EJ, Thiruchelvam M, Lungu C, Cory-Slechta DA, Fry JD, et al.
1271 Heritability, correlations and in silico mapping of locomotor behavior and
1272 neurochemistry in inbred strains of mice. *Genes, Brain Behav.* 2005;4: 209–228.
1273 doi:10.1111/j.1601-183X.2004.00102.x
- 1274 120. Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using
1275 lme4. *J Stat Softw.* 2015;67: 1–48. doi:10.18637/jss.v067.i01
- 1276 121. Saar K, Beck A, Bihoreau MT, Birney E, Brocklebank D, Chen Y, et al. SNP and
1277 haplotype mapping for genetic analysis in the rat. *Nat Genet.* 2008;40: 560–566.

- doi:10.1038/ng.124
122. Wang J, Williams RW, Manly KF. WebQTL: Web-Based Complex Trait Analysis. *Neuroinformatics*. Neuroinformatics; 2003. pp. 299–308. doi:10.1385/NI:1:4:299
123. Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, et al. The nature and identification of quantitative trait loci: A community's view. *Nature Reviews Genetics*. Nat Rev Genet; 2003. pp. 911–916. doi:10.1038/nrg1206
124. Lander E, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. *Nat Genet*. 1995;11: 241–247. doi:10.1038/ng1195-241
125. Broman KW, Sen S. A guide to QTL mapping with R/qtl. 2009.
126. Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. *BMC Bioinformatics*. 2008;9: 559. doi:10.1186/1471-2105-9-559
127. Smith JR, Hayman GT, Wang SJ, Laudederkind SJF, Hoffman MJ, Kaldunski ML, et al. The Year of the Rat: The Rat Genome Database at 20: A multi-species knowledgebase and analysis platform. *Nucleic Acids Res*. 2020;48: D731–D742. doi:10.1093/nar/gkz1041
128. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3-new capabilities and interfaces. *Nucleic Acids Res*. 2012;40: e115. doi:10.1093/nar/gks596
129. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol*. 2016;34: 525–527. doi:10.1038/nbt.3519
130. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al. Ensembl 2019. *Nucleic Acids Res*. 2019;47: D745–D751. doi:10.1093/nar/gky1113
131. Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq incorporating quantification uncertainty. *Nat Methods*. 2017;14: 687–690. doi:10.1038/nmeth.4324
132. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics*. 2014;30: 523–530. doi:10.1093/bioinformatics/btt703
133. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2002. Available: <https://www.r-project.org/>.
134. Fox J. An R Companion to Applied Regression. Third. Sage, Thousand Oaks CA; 2019. Available: <https://socialsciences.mcmaster.ca/jfox/Books/Companion/>
135. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. *Biometrical Journal. Biom J*; 2008. pp. 346–363. doi:10.1002/bimj.200810425
136. Wickham H. ggplot2 - Elegant Graphics for Data Analysis. Springer; 2016. Available: <https://www.springer.com/de/book/9780387981413>

Supporting Tables

Table S1. Quantitative RT-PCR analysis of *Tti2* mRNA expression in BN and SHR rats.

Tissue	$\Delta\Delta CT$ (SHR – BN)	<i>t</i>	df	<i>p</i> -value
Adrenal gland	-0.39 ± 0.13	1.84	9	0.099
Perirenal fat	1.15 ± 0.13	-4.83	8	0.0013
Hippocampus	-0.88 ± 0.1	3.5	8	0.0081
Kidney	-1.14 ± 0.12	5.31	8	0.00072
Liver	-0.85 ± 0.08	2.77	9	0.022
Soleus muscle	-1.49 ± 0.15	7.34	8	8.10E-05
Pancreas	-1.15 ± 0.11	2.49	8	0.037

Expression values were normalised to the mean expression of *Tti2* in BN. Note that lower cycle of threshold ($\Delta\Delta CT$) values indicate higher relative expression of a gene. Data is shown as means $\pm$ standard error of the mean; *t*, Student's *t*-test statistic; df, degrees of freedom.

Table S2. Non-synonymous amino acid substitutions in the SHR *Tti2* coding sequence.

Position	Conservation Score	Reference	SHR	Reference Amino Acid	Variant Amino Acid	Amino Acid Coordinate	Polyphenon Prediction	SIFT Prediction
64399852	0.909	T	G	E	D	247	benign	0.15
64401758	0.277	C	T	A	T	205	benign	0.71
64401779	0.567	T	C	K	E	198	benign	1
64402213	0.005	C	T	R	K	53	benign	0.9
64402331	0.001	A	G	C	R	14	benign	0.2
64402360	0	C	T	G	D	4	benign	1

Genomic sequence of SHR rats between positions 62.1 and 66.3 Mb on chromosome 16, which cover neurogenesis-glucose QTL, was scanned for non-synonymous amino-acid substitutions compared to reference genome using Variant Visualiser in Rat Genome Database. Within this interval, missense mutations were present only in the *Tti2* gene.

1329 Conservation score ranges from 1 (highly conserved) to 0 (not conserved). SIFT score
1330 ranges from 0 (damaging) to 1 (non-damaging). Positions are according to Rnor_5.0 genome
1331 assembly.

1332 **Table S3. RNAseq confirmed reduction of *Tti2* mRNA expression in SHR-*Tti2*^{+/-} rats**
1333 **compared to wild type SHR littermates.**

Tissue	beta	se	<i>p</i> value	<i>q</i> value
Hippocampus	-0.54	0.07	1.40E-15	2.8E-11
Liver	-0.53	0.08	7.7E-11	1.8E-07
Fat	-0.46	0.07	1.7E-11	3.5E-07
Muscle	-0.63	0.06	3.70E-22	6.7E-18

1334

Supporting Figure Captions

Fig. S1. Metabolic phenotyping of three-months old heterozygous SHR-*Tti2*^{+/-} rats and wild type SHR- *Tti2*^{+/-} littermates (denoted as SHR).

Details of statistical analysis are in Table 2. Abbreviations: BAT, brown adipose tissue; GSH, glutathione; HDL, high-density lipoprotein; TG, triglycerides.

Fig. S2. Top canonical pathways enriched among differentially expressed genes between SHR-*Tti2*^{+/-} rats and wild type SHR littermates.

Analysis was performed with Ingenuity pathway analysis (IPA), which, in addition to calculating enrichment, predicts activation (positive Z-score, red) or inhibition (negative Z-score, blue) of molecular pathways from the direction and magnitude of expression changes using curated database. Grey bars depict enriched pathways for which activation status could not be predicted. Vertical green dashed line indicates *p* value threshold of 0.05.

Fig. S3. Predicted regulator networks effects involved in glucose homeostasis in livers of SHR-*Tti2*^{+/-} rats

Differentially expressed genes in livers of SHR-*Tti2*^{+/-} rats and wild type SHR littermates were analysed using IPA. Up- (magenta) and downregulated genes (green; middle tier) connect the potential upstream regulators (upper tier) to downstream outcomes (bottom tier). Edges represent relationships derived from curated databases.

Fig. S4. Frequencies of single- and multi-tissue human *TTI2* eQTL.

821 genomic variants underlying 2177 eQTL ($p < 1e-4$) extracted from eQTL EBI catalogue (<https://www.ebi.ac.uk/eqtl/>) were clustered according to the number of distinct tissues or cell types in which eQTL were detected. Multiple eQTL from different data sets derived from the same cell or tissue type were scored as a single-tissue eQTL.

1358 **Supporting Information Files**

1359 **File S1. Ingenuity canonical pathways.**

1360 IPA canonical pathways enriched in differentially expressed genes in SHR-*Tti2*^{+/-} vs. wild type
1361 SHR rats in the hippocampus, liver, muscle and perirenal adipose tissue.

1362 **File S2. Ingenuity upstream regulators.**

1363 Affected upstream regulators predicted by IPA from differentially expressed genes in SHR-
1364 *Tti2*^{+/-} vs. wild type SHR rats in the hippocampus, liver, muscle and perirenal adipose tissue.
1365 Activation Z-score is deduced from the direction and magnitude of the gene expression
1366 changes.

1367 **File S3. Ingenuity downstream functions and diseases.**

1368 Functions enriched among differentially expressed genes in SHR-*Tti2*^{+/-} vs. wild type SHR
1369 rats in the hippocampus, liver, muscle and perirenal adipose tissue. IPA deduces the
1370 activation Z-scores from the direction and magnitude of the gene expression changes.

1371 **File S4. Human *TTI2* eQTL.**

1372 Human eQTL catalogue (<https://www.ebi.ac.uk/eql/>) was queried for variants associated with
1373 changes in the *TTI2* mRNA expression. Significant eQTL were defined by *p* value < 1e-4.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5